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General Introduction
Over the past few decades, considerable attention has been given to the long-
term reproductive function of females after undergoing cancer treatment 
(Gosden, 2009). Oncotherapy, such as chemotherapeutic agents and radio-
therapy, can damage the ovaries and induce premature ovarian insufÀ ciency 
(POI) (Oktem and Oktay, 2007; Wallace et al., 2003; Wallace et al., 2005) . 
We do know that fertility preservation is an important issue for cancer pa-
tients (Tschudin and Bitzer, 2009) and the need for counselling patients about 
fertility preservation is an essential part of the quality of life after treatment 
(Letourneau et al., 2012). There are several options for fertility preservation. 
These options include, amongst others, accelerated IVF treatment followed 
by cryopreservation of embryos or vitriÀ cation of mature oocytes, and cryo-
preservation of ovarian tissue strips. Obviously, IVF treatment is not a suitable 
option for young (prepubertal) female cancer patients. For this group of pa-
tients cryopreservation of ovarian strips is currently the only available option. 
After re-transplantation of cryopreserved/thawed cortical tissue it takes 
about 4-5 months for resumption of endocrine and reproductive function 
(Baird et al., 1999; Nisolle et al., 2000; Liu et al., 2008). Unfortunately, the 
re-transplanted cortical strips only retain ovarian function for a relatively 
short time and within three years of transplantation, in nearly all patients, 
the strips cease to function (Donnez et al., 2006; Oktay, 2006; Tao and Del, 
2008). 
The À rst reason for this short period of time is that the quantity of cryo-
preserved/thawed cortical tissue in a graft and consequently the number of 
follicles contained within, is limited. A second reason for the short longevity 
is that the cortical tissue is grafted without a vascular anastomosis. There-
fore, the survival of the graft is entirely dependent on neovascularisation, a 
process that takes at least a week (Israely et al., 2004; Israely et al., 2006). 
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During this time the graft will already have sustained ischemic damage re-
sulting in massive loss of primordial follicles, being ultimately responsible for 
the limited functional life span of the graft (Baird et al., 1999; Gosden, 2008; 
Nisolle et al., 2000; Oktay and Karlikaya, 2000; Silber et al., 2008).
As an alternative to ovarian tissue transplantation whole, intact, ovary trans-
plantation has been explored. 
Cryopreservation of the intact ovary with its intact pedicle and vascular 
supply might overcome the problem of ischemic damage. After a successful 
re-anastomosis the ovary, theoretically, could maintain long-term endocrine 
and reproductive functions (Bromer and Patrizio, 2008; Imhof et al., 2006; 
Silber et al., 2008; Tao and Del, 2008).
Two major problems with intact organ cryopreservation and re-transplanta-
tion have hampered the clinical implementation of this procedure. First, the 
development of a successful cryopreservation protocol for intact human ova-
ries has thus far been lacking. Secondly, the feasibility of performing a per-
fect vascular re-anastomosis of the whole organ without leakage or thrombus 
formation, is a prerequisite for a successful recovery of fertility. 
The development of an effective cryopreservation protocol for large-sized 
intact ovaries is problematic due to: 
i. the heat transfer between the core and the periphery of a large or-
gan might be an insuperable difÀ culty. 
ii. the establishment of adequate stromal and cortical diffusion of the 
cryoprotectants (Bedaiwy et al., 2003; Falcone and Bedaiwy, 2005). 
Inadequate perfusion may lead to intravascular ice formation with 
subsequent vascular injury. 
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The cryoprotectant and cryopreservation protocol that combine maximal per-
meation capacity, minimal toxicity and maximal inhibition of ice crystal for-
mation may be different for each cell and tissue type (Martinez-Madrid et al., 
2004; Martinez-Madrid et al., 2007). In this thesis we describe our efforts to 
establish the optimal procedure for the cryopreservation of an intact ovary. 
In our study we want to use an animal model system, as much as comparable 
to human ovaries with respect to size, monthly cycle and number of follicles 
that mature per cycle. In this model system we will test different cryopres-
ervation protocols. 
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Aims and objectives of the thesis:
The aim of the study is to establish the optimal procedure for cryopreserva-
tion of a intact ovary.
The objectives of this thesis are:
x To select the animal model that is best comparable to the human 
ovary.
x To establish a cryopreservation procedure that provides excellent 
cryoprotection in this animal model
x To estimate/investigate the effectiveness of the procedure. 
Therefore different assays should be developed and consecutively 
validated:
o an assay based on 17ş-oestradiol production in vitro as a 
marker for (pre-antral) follicular survival.
o an assay based on the glucose/lactate metabolism as a 
quantitive parameter of cryodamage on ovarian tissue.
o validation of the glucose/lactate assay comparing the 
results with the histology and occurrence of apoptosis in 
cryopreserved tissues.
x To investigate the effect of perfusion and submersion of different 
cryoprotective agents in the different tissue compartments of the 
ovary.
x To examine the optimal cryopreservation of different ovarian tissue 
compartments (cortex, subcortex and medulla).
x After optimization of the technique a few human ovaries will be 
cryopreserved and tested.
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Introduction
New protocols in the early diagnosis and treatment of cancer have led to ma-
jor improvements in the long-term survival of patients. However, aggressive 
chemotherapy or radiotherapy of the pelvic region, often lead to infertility, 
due to the damage of the follicles and/or oocytes that are present in the 
ovaries. In women the probability of sterilization due to cancer therapy var-
ies with age, the type of treatment, and the follicular reserve in the ovary. 
Safeguarding their reproductive potential is a very important issue for women 
that have not yet started or completed their family, and even more so in 
pre-pubertal girls. Several options, some of which are still in the experimen-
tal phase, can now be offered to these women to (partially) preserve their 
fertility. 
In this review, we will, after brieÁ y describing the anatomy and physiology of 
an ovary, discuss the detrimental effects of chemotherapy and radiation on 
ovarian function. Subsequently, the various options that are currently avail-
able or are still in an experimental phase, for preserving fertility in women 
and pre-pubertal girls, will be discussed. These options (with the exception of 
option (i)), deal with cryopreserving either oocytes, embryos or ovarian tissue 
until the patient has been cured. 
i. Minimizing the effects of radiation of the inner pelvic region by 
transposing the ovaries from the radiation area.
ii. Standard IVF procedures can be offered to women who are awaiting 
chemotherapy and radiotherapy for neoplastic disease. This proce-
dure results in the generation of embryos that can be transferred 
after recovery of the disease. This option has its limitations, since 
it not only requires the presence of a male partner, but also delays 
cancer treatment during ovarian stimulation. In addition, the num-
ber of embryos that can be produced is restricted, and the chance of 
achieving a pregnancy after transfer of a cryo-preserved embryo is 
only 8-30%. Furthermore, the presence of estrogen-sensitive tumors 
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is a contra-indication for this type of treatment, as high estradiol 
levels are induced during a normal IVF procedure, although alterna-
tive stimulation protocols with aromatase-inhibitors are nowadays 
available for these speciÀ c patients. Most importantly, this treat-
ment is not an option for pre-pubertal girls, or for post-pubertal girls 
who are not yet involved in a stable relationship.
iii. Aspiration of oocytes, followed by cryopreservation and IVF (if nec-
essary preceded by in vitro maturation). This option has already 
been applied to a number of patients. Although the same drawbacks 
that apply to standard IVF are applicable, this procedure is mainly 
aimed at the treatment of post-pubertal girls/young women without 
a stable relationship. Only limited scientiÀ c data are currently avail-
able to substantiate its efÀ cacy and long-term safety. 
iv. As an alternative, cryopreservation of small ovarian cortex strips 
containing primordial follicles can be offered. After the patient has 
been cured, these cortex strips can subsequently be retransplant-
ed either heterotopically or orthotopically. This procedure has been 
successfully used to re-establish female fertility in humans in a lim-
ited number of cases. A major problem with these avascular implants 
however is their relative short life expectancy and follicular loss due 
to long term ischemic injury directly after reimplantation.
v. Cryopreservation and subsequent reimplantation of intact ovaries 
may be a valuable addition to the existing array of options, espe-
cially for pre-pubertal girls and post-pubertal girls/women who are 
not in a stable relationship. An important safety issue relating to 
this procedure is obviously the chance of reintroduction of malig-
nant cells that may be present in the cryopreserved intact ovary. For 
this reason, patients with solid types of tumor and diffuse types of 
cancer such as leukemia that have a high chance of metastasizing to 
the ovaries, will have to be excluded from this kind of therapy. The 
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cryobiological and surgical aspects of the preservation and retrans-
plantation of an organ in toto, is technically clearly more challeng-
ing than the cryopreservation and transfer of isolated cells or tissue 
strips. The advantages of this approach are obvious immediate re-
vascularization of the transplanted ovary ensures that less ischemic 
damage is inÁ icted to the ovarian tissue post-thawing, and that more 
follicles will survive. In addition menses, normal long term reproduc-
tive functions, and normal hormonal status will be restored.
Finally, we will discuss the safety aspect of the procedure. Inevitably the 
autotransplantation of cortical strips or intact ovaries carries the risk of rein-
troducing malignant cells from the graft into the recipient.
The increase in knowledge of the biology and treatment of cancer has been 
accompanied by an increase in the efÀ cacy of cancer therapies. Long term 
survival rates for many cancer types have therefore increased accordingly 
(Gatta et al., 2009). Consequently, the quality of life of cancer survivors is 
becoming an important issue.
The possibility to have genetically concordant progeny is for many people an 
event that is essential for an unrestricted quality of life as an adult (Schover, 
2009). The loss of fertility that may result from cancer therapy, is therefore 
an additional complication on top of an already difÀ cult period spent con-
quering a devastating disease.
With this in mind, it is of the utmost importance to explore the possibilities 
for fertility preservation in patients that are to be treated with a gonado-tox-
ic therapy. For post-pubertal boys and men, this can be achieved relatively 
easy via the cryopreservation of their semen prior to start of the therapy. For 
pre-pubertal boys this is not an option, as semen production is initiated during 
puberty. Also for this group of patients options for fertility preservation are 
being developed.
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In this paper we conÀ ne ourselves to fertility preservation in female patients. 
We discuss the causes of anti-cancer therapy-related infertility, and review 
the current options for fertility preservation. We illustrate this matter with 
two case reports from our own clinical practice. In addition we discuss some 
as yet experimental procedures, that may in the future be offered to patients 
requiring fertility preservation.
Ovaries, oocytes and female reproduction
The human ovary is spherical structure with a mean volume of 7 cm3 (range 
2-15 cm3 Munn et al., 1986). The inner ovarian mass, the medulla, consists 
mainly of stromal cells and contains the larger blood vessels. The outer layer 
of the ovary consists of the cortical tissue, spanning 2-3 mm. This tissue is rich 
in extra-cellular matrix proteins and poor in capillaries, and contains the vast 
majority of the follicles containing oocytes that comprise the ovarian reserve. 
The most important role of the follicle is to protect the oocyte, and support 
its development. Follicles comprise of layer(s) of theca cells and granulosa 
cells. Different stages of follicles can be distinguished, ranging from primor-
dial follicles to primary follicles, and via secondary À nally to tertiary (antral) 
follicles.
In contrast to males in whom spermatogenesis is a continuous process re-
sulting in the uninterrupted generation of fresh spermatozoa, in women a 
À xed number of oocytes is formed during embryogenesis from 1000-2000 germ 
cells. These germ cells are present in the human embryo at 30 days after 
conception. After 9-10 weeks, these cells transform to oogonia (Baker, 1972), 
that degenerate for the greater part between 10 and 20 weeks of gestation. 
After 5 months of gestation, the À rst meiotic division is initiated in the re-
maining oogonia, resulting in the differentiation to primary oocytes. At this 
stage the meiotic division process is arrested, and the oocytes enter a stage 
of dormancy (Wandji, 1996). At birth only 300.000 to 400.000 oocytes remain 
in the ovaries. From birth, the number of oocytes gradually decreases, and at 
the beginning of puberty around 200.000 oocytes remain. Under the inÁ uence 
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of pituitary gonadotropic hormones (Gougeon, 1996 Oktay, 1997), each month 
a cohort of primary oocytes is recruited, and resumes development. Usually 
only one primary oocyt completes the À rst meiotic division. This secondary 
oocyt again enters a stage of dormancy, and is ovulated. The second dormant 
stage is only lifted after fertilization by a sperm cell. Around the age of 50 
years, the total oocyte reserve is almost depleted and the woman enters 
menopause. In addition to age, several factors may affect the follicular re-
serve, leading to an early exhaustion and to premature ovarian insufÀ ciency 
(POI). These factors include fertility-threatening therapies that are discussed 
in more detail in the next section. 
Effects of radio- and chemotherapy on female fertility
Chemotherapy
Cytotoxic therapy may affect all components of the follicle, including gran-
ulosa cells, theca cells, and of course the oocyt itself (Sobrinho et al., 1971 
Blumenfeld et al., 1999). In addition, interactions between these cell types 
that are required for oocyt development may be disturbed, resulting in the 
demise of the oocyt. Damage may become manifest by reduced ovarian 
weight, stromal À brosis and in a reduction in the number of oocytes and ovar-
ian follicles (Warne et al., 1973 Meirow et al., 1999 Oktem & Oktay, 2007).
The effect of chemotherapy on fertility is dependent on the type of the cy-
totoxic agent, the dose, and the duration of the therapy. Alkylating agents 
such as cyclophosphamide, L-phenyalanine mustard, and chlorambucil per-
manently damage ovarian tissue by interacting with DNA (Meirow et al., 1999 
Manger et al., 2006 Oktem & Oktay, 2007). Analysis of a group of 138 young 
females receiving the alkylating agent busulfan as a preparative regimen for 
total body irradiation (TBI) indicated that 83% of these women showed signs 
of fertility impairment, demonstrating the potentially very severe effects of 
this type of compounds (Borgmann-Staudt et al., 2011). Mertens et al. (1998) 
showed an even higher percentage of 99% in gonadal dysfunction for women 
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receiving allogeneic haematopoietic stem cell transplantation. The cumula-
tive dose of the cytotoxic drug being administered is an important factor in 
determining the level of ovarian insufÀ ciency (Goldhirsch et al., 1990). Per-
manent ovarian insufÀ ciency was more often induced when high dosages of 
drugs were administered during a short period of time, compared to low doses 
given over a longer time (Koyama et al., 1977). 
In addition the age of the patient is pivotal in determining the amount of dam-
age that is inÁ icted to the ovary. Older women, with an already decreased 
number of primordial follicles, have a higher risk of developing acute com-
plete POI, compared with young women who still possess numerous primordial 
follicles (Schilsky et al., 1981 Sanders et al., 1996 Tauchmanova et al., 2002). 
Prepubertal girls seem less vulnerable to cytotoxic drugs than adults (Chiarelli 
et al., 1990). This may be explained by the fact that several chemothera-
peutical drugs affect DNA replication and/or RNA and protein synthesis, and 
are therefore targeted at metabolically active cells. In prepubertal ovaries 
all follicles are in a dormant, metabolically quiescent state, and therefore 
less prone to chemotherapy induced damage. In contrast, in adult ovaries a 
number of follicles will be in an active state, and therefore more prone to 
chemotherapy induced damage. Nicosia et al. (1985) actually showed in ovar-
ian autopsy material derived from patients having received chemotherapy, 
that the number of growing follicles was reduced, whereas the number of 
primordial follicles remained the same. 
Radiotherapy
Similar to the effects of chemotherapeutical agents on DNA integrity, ionizing 
radiation, amongst other effects, also interferes with DNA function. As a con-
sequence, radiotherapy may negatively affect the ovarian reserve. Analogous 
to chemotherapy, the (cumulative) dose and the fractionation schedule de-
termine the degree of damage to the ovary (Gosden et al., 1997). The human 
oocyte is exceptionally sensitive to radiation (Howell & Shalet, 1998) and the 
estimate of the LD50 (the lethal dose needs to kill half the total number of 
oocytes) seems to be less than 2 Gy (Wallace et al., 2003). Also for radiation 
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therapy, the age of the patient is an important factor in determining the level 
of damage. A dose of 4 Gy leads to sterility in 30% of young women, and in 
100% of women over 40. Not surprisingly, the combination of radiotherapy 
with chemotherapy increases the risk of POI (Williams et al., 1999 Wallace 
et al., 2005 Chemaitilly et al., 2006). Abdominal radiotherapy in combination 
with alkylating agents increased the risk of POI 27-fold (Byrne et al., 1992). 
By the age of 31, 42% of patients treated with this combination therapy, was 
postmenopausal, compared with 5% of women in the normal population. 
Effects on pregnancy and health of newborns
In addition to their effects on oocytes and follicles, chemotherapy and radio-
therapy may also inÁ uence uterine function. Radiation may lead to impaired 
uterine growth in premenarchal girls and failure of uterine development 
during pregnancy, leading to miscarriages, premature births and intrauter-
ine growth retardation (Ogilvy-Stuart et al., 1997 Critchley, 1999 Critchley 
et al., 1992 2002 Wallace et al., 2005). Comparable results were described 
by Salooja et al. (2001), who showed that in women who receive total body 
irradiation prior to autologous or allogeneic stem cell transplantation, are at 
high risk for maternal and fetal complications. These problems are probably a 
consequence of uterine vascular damage and reduced elasticity of the uterine 
musculature.
Current options for fertility preservation
Ovarian transposition
A way to prevent damage to the ovaries caused by ionizing radiation therapy 
applied to the pelvic region, is to surgically move the ovary temporarily to 
a location outside the À eld of radiation (Hadar et al., 1994 Howard, 1997). 
This procedure, referred to as oophoropexy, can be performed laparoscopi-
cally. Potential ovarian insufÀ ciency following transposition may occur if the 
ovaries are not entirely moved outside the À eld of radiation, or when they 
spontaneously migrate back to their original position. Ovarian failure can also 
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occur when the ovarian vascular pedicle is compromised by the surgical pro-
cedure (Feeney et al., 1995). Oophoropexy is a safe and effective procedure, 
allowing preservation of ovarian function in 80% of cases (Bisharah & Tulandi, 
2003).
VitriÀ cation of oocytes
Cryopreservation of mature or immature oocytes is an obvious approach to 
preserve fertility. As no fertilization of the oocytes is yet required, this is 
option is especially suitable for women without a partner. The collection of 
mature oocytes requires stimulation with follicle stimulating hormone (FSH). 
This procedure, that may have to be repeated to obtain a sufÀ cient number 
of oocytes, takes at least two weeks, and is therefore only suitable for wom-
en for whom it is safe to postpone their cancer treatment. The use of high 
doses of FSH makes this option unsuitable for women with oestradiol-sensitive 
breast tumors, as high levels of oestradiol are induced by the FSH treatment 
(Sonmezer & Oktay, 2006) This caveat may be circumvented by the simultane-
ous use of aromatase inhibitors /anti oestrogens such as letrozole or tamox-
ifen (Oktay et al., 2005b Sonmezer & Oktay, 2006). Alternatively, immature 
oocytes can be collected without prior stimulation. This procedure may also 
be used for young (prepubertal girls). Evidently, these immature oocytes must 
be matured in vitro (IVM) before they can be fertilised (Gosden, 2005). 
After collection of the oocytes, they have to be cryopreserved in liquid nitro-
gen for long term storage. The formation of ice crystals during the freezing 
process may severely damage the oocyte, rendering it useless for further use. 
This is especially the case for mature oocytes, as they possess a fragile and 
sensitive meiotic spindle. Immature oocytes are in this respect less sensitive. 
Cryodamage can be prevented by freezing the oocytes in the presence of 
cryoprotective agents via speciÀ c protocols, either by slow freezing, or via 
vitriÀ cation (Cao et al., 2009 Chian et al., 2009 Kuwayama et al., 2005). Dur-
ing the latter procedure, that appears to result in more oocytes surviving the 
process undamaged, the oocytes are frozen extremely rapidly (> 12.000 °C/
minute), in the presence of high concentrations of cryoprotectant, resulting 
in the prevention of ice crystal formation. 
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A consequence of the cryopreservation procedure (either slow freezing or 
vitriÀ cation) is hardening of the zona pellucida. Therefore, cryopreserved 
oocytes can only be fertilized via intracytoplasmatic sperm injection (ICSI). 
As the pregnancy rate per cryopreserved oocyte is approximately 3% (Kuway-
ama et al., 2005 Cobo et al., 2007 Homburg et al., 2009), a large number 
of oocytes, equivalent to several stimulation cycles and/or oocyte retrieval 
procedures, are required to achieve a reasonable chance of progeny. The 
exact number of children conceived with cryopreserved oocytes is unknown, 
but it is estimated to be over 500 worldwide. Postnatal parameters such as 
birth weight and incidence of congenital anomalies were comparable with the 
reference population, indicating the safety of this procedure (Borini et al., 
2007 Chian et al., 2008).
Cryopreservation of embryos
For women with a partner, the generation and cryopreservation of embryos is 
a suitable option. Obviously, this option will generally require ovarian stimu-
lation, and is therefore subject to the same limitations mentioned previously 
regarding the collection and cryopreservation of mature oocytes – the cancer 
treatment has to be postponed to allow for one or more ovarian stimula-
tion(s), and extreme caution has to be taken when stimulating women with 
hormone sensitive tumors. The factor time may be circumvented by skipping 
the stimulation with FSH and collect immature oocytes instead. Evidently, 
in this case IVM has to be performed prior to fertilisation of the oocytes. 
Employing tamoxifen or letrozole based stimulation regimes may be used in 
the case of hormone sensitive tumors (see previous paragraph) (Oktay et al., 
2005a, 2005b Sonmezer & Oktay, 2006). Oktay et al. (2005b) has shown that 
in cancer patients who had been stimulated with this compound, recurrence 
rates were not elevated compared with cancer patients who had not been 
receiving any ovarian stimulation. However we should note that the follow up 
period was conÀ ned to a limited number of years only. 
Theoretically, in women with hormone sensitive tumors oocytes can also be 
collected in a spontaneous (non-stimulated) cycle. However, the very limit-
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ed number of oocytes that can be collected this way (one or two per cycle) 
makes this a very inefÀ cient option and is therefore not advisable (Brown et 
al., 1996).
Embryo cryopreservation is an established and efÀ cient technique, with re-
ported implantation rates per thawed embryo between 8 and 30% (Frederick 
et al., 1995 Selick et al., 1995 Wang et al., 2001 Son et al., 2002 Senn et al., 
2006), that has resulted in the birth of tens of thousands of children world-
wide. In the future, new cryopreservation techniques such as vitriÀ cation 
may further improve the efÀ ciency of this technique (Kuwayame et al., 2005)
Case report A: Emergency IVF in a patient with breast cancer
Mrs. X was diagnosed 3 years ago with breast cancer. She then underwent a 
lumpectomy of the right breast, and received radiotherapy. Shortly thereaf-
ter a unilateral recurrence was found, and a mastectomy with lymph node 
dissection was performed. Pathologic examination revealed an invasive duct-
al carcinoma, positive for estrogen and progesterone receptors. No tumor 
cells were found in the lymph nodes, and no other indications for metastatic 
disease were found. Additional chemotherapy courses were planned.
At this stage the patient, now 35 years of age, and her partner visited the 
Centre for Reproductive Medicine of our hospital, and expressed their inter-
est in fertility preservation. After establishing that the current reproductive 
status of herself as well as of her partner showed no abnormalities, the 
possibilities for fertility preservation were discussed. Although oocyte vitri-
À cation and ovarian tissue banking were in theory viable options, the couple 
was counseled to proceed with an emergency IVF-ICSI attempt, followed by 
cryopreservation of the embryos, as this would probably give the highest 
chance of progeny within the time limit set by the oncologist.
The ovarian stimulation protocol was started one month after the mastecto-
my. Regarding the hormone receptor positive status of the tumor, a regimen 
combining FSH and letrozol was selected in order to avoid the high oestradiol 
levels associated with ovarian hyperstimulation. The treatment eventually 
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resulted in the retrieval of 13 oocytes, 12 of which could be inseminated via 
ICSI. Of the 7 resulting embryos, 3 were eligible for cryopreservation. The ef-
À cacy of the letrozol treatment was demonstrated by the À nding that during 
the stimulation with FSH, oestradiol levels did not rise beyond 1000 pmol/L. 
The patient than completed 5 cycles of chemotherapy. In addition, she re-
ceived adjuvant hormonal therapy. Menses had stopped and the patient suf-
fered from hot Á ushes. Two years later at age 37, the patient wanted to 
achieve pregnancy. After discontinuation of medication, the hot Á ushes di-
minished and menses did resume. Five months later the patient conceived 
spontaneously, but unfortunately the pregnancy ended in an abortion. As 
further spontaneous conceptions did not occur, two cycles of fresh IVF were 
performed. Although the second cycle resulted in a pregnancy, this again 
ended in an abortion. The patient is now being prepared to receive the em-
bryos that were cryopreserved prior to the start of her chemotherapy.
Cryopreservation of ovarian cortical tissue strips
As mentioned previously, each fertility preservation option is aimed at a spe-
ciÀ c group of patients. When the patient is prepubertal, when there is no 
partner is available for the generation of embryos, or when the cancer treat-
ment cannot be postponed in order to perform ovarian stimulation, cryopres-
ervation of ovarian tissue strips may be an alternative approach. Silber et al. 
(2005) showed previously that transplantation of fresh (non cryopreserved) 
ovarian cortex strips between identical twin sisters was actually feasible. The 
development of efÀ cient freezing and thawing protocols for cortex strips has 
rendered this technique applicable for fertility preservation purposes and has 
recently led to the thirteenth live birth (Donnez et al., 2011). 
Although still experimental, this option is nowadays being performed on an 
increasing scale. Cortical fragments can be obtained laparoscopically, and 
slow frozen using DMSO as a cryoprotectant. Care should be taken to minimize 
the thickness of the cortical strips to 1 mm, to facilitate diffusion of the cry-
oprotectant into the tissue. In addition, thin fragments will suffer less from 
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ischemic damage, which is a serious problem after retransplantation. A signif-
icant proportion (60-95%) of (growing) follicles that survive the freezing and 
thawing process, is actually lost due to warm posttransplantation ischemia 
(Baird et al., 1999 Nisolle et al., 2000 Candy et al., 2000 Aubard et al., 1999, 
Aubard, 2003 Liu et al., 2002). Cortical strips can be autotransplanted heter-
otopically (for instance subcutaneous in the forearm), or orthotopically. Thus 
far, only orthotopic transplantation has led to the birth of a number of healthy 
offspring (Donnez et al.,2004 Meirow et al.,2005, 2007 Demeestere et al., 
2006 2007 2010 Andersen et al.,2008 Schmidt et al., 2011 Ernst et al., 2010). 
Cryopreservation of ovarian cortical strips is applicable for a wide range of 
different patients. Conception may require artiÀ cial reproductive techniques 
like IVF or ICSI, but may occur spontaneously as well. An additional advantage 
of this technique is resumption of the regular hormonal processes, leading 
to the reversal of the postmenopausal status that many patients experience 
after their cancer therapy. Follicular development and restoration of ovarian 
function usually occur 4-5 months after a transplantation procedure ( Donnez 
et al., 2006a 2008), as more than 120 days are required to initiate follicular 
growth and approximately 85 days to the reach À nal maturation stage from a 
pre-antral follicle (Gougeon, 1985, Oktem & Oktay, 2008). Unfortunately, the 
survival time of a single autotransplanted number of strips is usually limited 
to a few months, with exceptions of survival up to approximately 3 years (Kim 
et al., 2009 Meirow et al., 2007 Silber et al., 2008a), requiring another surgi-
cal intervention to transplant a new set of cortex strips. 
Case report B: Ovarian tissue cryopreservation in a patient with Hodg-
kin’s lymphoma
Mrs. Y was diagnosed with Hodgkin’s lymphoma at the age of twenty. As she 
was to start with six cycles of chemotherapy the next month, she visited the 
Centre for Reproductive Medicine to discuss the options for fertility preser-
vation. 
Although the patient was at the time in a steady relationship, she regarded 
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herself to young to start emergency IVF, as this would confront both herself 
and her partner with the deÀ nitive choice of having children together in 
the future. Ovarian hyperstimulation followed by cryopreservation of the 
retrieved oocytes was not considered an optimal option, as the time to the 
start of her chemotherapy was relatively short, allowing for only one cycle of 
hyperstimulation. As a consequence, only a limited number of oocytes would 
be obtained.
Eventually the choice was made for cryopreservation of ovarian cortical 
strips. At that time we could not offer her this procedure ourselves so we 
referred her to another centre. Biopsies of both ovaries were taken via a 
laparoscopic procedure, and 13 strips were cryopreserved. She then started 
with the chemotherapy. Since then, she has had two relapses, which were 
treated with chemotherapy, radiotherapy, and stem cell transplantation. 
At the age of 27, the patient and her partner visited our Centre as she 
wished to conceive. She had now been in complete remission for 3 years. 
Hormonal examination showed that she was postmenopausal, indicating that 
both spontaneous conceptions as well as IVF treatments were no options to 
achieve pregnancy. The couple was referred back to the clinic where her 
ovarian tissue was cryopreserved, and is now considering autotransplanta-
tion of the ovarian cortical strips.
Future options for fertility preservation
Several alternative procedures are being evaluated to expand the current 
array of fertility preservation options. These include the isolation and cryo-
preservation of follicles from ovarian tissue that is harvested laparoscopically 
(Bedaiwy & Falcone, 2007 Feigin et al., 2007). However, isolation of follicles 
by either mechanical or enzymatic means is difÀ cult, especially from human 
ovaries (Dolmans et al., 2006). In addition, this approach requires different 
cryopreservation techniques than for oocytes and embryos, and sophisticated 
in vitro maturation protocols to obtain oocytes that can be fertilized in vitro 
by IVF or ICSI.
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A more promising future option may comprise the cryopreservation of an in-
tact ovary, including its vascular pedicle. The vascular pedicle can be used 
to reconnect the thawed ovary to the circulation, thereby preventing the 
devastating effects of warm ischemia that is known to deplete the follicles 
in ovarian tissue transplanted without vascular anastomosis (Newton et al., 
1996 Nisolle et al., 2000 Candy et al., 1997 Aubard et al., 1999 Baird et al., 
1999 Aubard, 2003 Liu et al., 2008). However, the successful cryopreservation 
of an intact organ represents an immense technical challenge. Pioneering 
work by Parrot (1960) on murine ovaries provided proof of principle. Later re-
ports showed that also in other mammalian species this proved to be a viable 
approach. Freezing and autologous grafting of whole ovaries has now been 
performed in rabbits (Chen et al., 2005), pigs (Imhof et al., 2004), and sheep 
(Bedaiwy et al., 2003 Arav et al., 2005 Imhof et al., 2006), yielding promis-
ing results. In rats (Wang et al., 2002) and sheep (Imhof et al., 2006), this 
procedure has actually resulted in live offspring. In humans, transplantation 
of fresh (non-cryopreserved) intact ovaries has also been performed success-
fully. Ovarian autotransplantation in the upper arm was performed before 
pelvic irradiation (Leporrier 1987, Hilders et al., 2004). Over a period of 16 
years, the ovary remained functional (Leporrier et al., 2002). A À rst full-term 
pregnancy was obtained using orthotopic fresh whole ovary transplantation 
between identical twin sisters (Silber et al., 2008b).
Cryopreservation of an intact human ovary with its vascular pedicle has been 
described previously (Martinez-Madrid et al., 2004, 2007 Bedaiwy et al., 
2006). These authors showed that perfusion of the ovary with cryoprotect-
ants led to a certain degree of protection from cryodamage. The subsequent 
autotransplantation of frozen and thawed human ovaries, however, has thus 
far not been performed. A major obstacle in this respect is the much larger 
volume of human ovaries compared with murine and ovine ovaries (Gerritse 
et al., 2008). This larger volumes hampers the sufÀ cient diffusion of cryo-
protectant into the tissue (Donnez et al., 2006b). In addition, the freezing 
kinetics in a bulky organ are bound to be completely different from those in 
a small volume organ (Pegg, 2005). Finally, all components of the organ, in-
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cluding the vascular pedicle, the inner vasculature, the stromal tissue and of 
course the follicles, should be veriÀ ably protected before retransplantation 
into human subjects can be even considered. This requires the development 
of biologically relevant assays that are able to quantify cryodamage in a re-
liable fashion. Understandably, efforts have focused mainly on the survival 
of the follicles within the intact cryopreserved ovary. This has been done by 
conventional histology (Bedaiwy et al., 2003, Arav et al., 2005 Courbiere et 
al., 2005, 2006 Martinez-Madrid et al., 2004 Imhof et al., 2006 Baudot 2007), 
immunohistochemistry (Arav et al., 2005 Bedaiwy et al., 2006), determining 
the frequency of apoptosis (Bedaiwy et al., 2003, 2006 Martinez-Madrid et 
al., 2007), using survival/viability/proliferation assays (Bedaiwy et al., 2003, 
2006 Martinez-Madrid et al., 2004, Arav et al., 2005, Courbiere et al., 2005, 
2006 Imhof et al., 2004 Baudot et al., 2007, Onions et al., 2008), transmis-
sion electron microscopy (Martinez-Madrid et al., 2007) and estradiol assays 
(Huang et al., 2008 Isachenko et al., 2007 Gerritse et al., 2010). These stud-
ies have produced relevant information on the prevention of cryodamage in 
follicles, but have largely left out the main component of the ovary, namely 
the stromal cell compartment that constitutes over 95% of the ovarian mass. 
An additional reason to focus also on survival of stromal cells is the observa-
tion that these cells are vital for optimal follicular development (McLaughlin 
and McIver, 2009). Finally, the metabolically active stromal cells have been 
described to be more sensitive to cryodamage than the quiescent primordial 
oocytes (Kim et al., 2004). These observations emphasize the need for a cryo-
preservation protocol that not only efÀ ciently preserves the follicles/oocytes, 
but the stromal cell compartment as well. 
We therefore decided to develop an assay that is capable of quantifying the 
basal metabolism of the bulk of the tissue as a measure of cryodamage. For 
this purpose we measured the uptake of glucose and the release of lacate by 
cultured ovarian tissue fragments. We used bovine ovaries as a model system, 
as they are comparable to human ovaries with respect to size, monthly cycle, 
and number of follicles that mature per cycle (Gerritse et al., 2008). In this 
model system we were able to test different cryopreservation protocols. Our 
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results show that both immersion of the bovine ovary in cryoprotectant, com-
bined with perfusing it for a prolonged period of time, resulted in a nearly 
complete protection of the ovarian metabolism. This procedure did not affect 
the endothelium of the vascular pedicle and the inner vasculature (Gerritse 
et al., submitted). We plan to xenotransplant optimally cryopreserved bovine 
ovaries into immune deÀ cient rats, in order to test the ability of the follicles 
to develop in vivo and produce mature oocytes.
Safety aspects of ovarian tissue autotransplantation
A major point of concern when autotransplanting ovarian tissue to cured 
cancer patients, is the possibility that (metastasized) tumor cells are pres-
ent in the ovarian graft and are reintroduced to the patient (Shaw et al., 
1996). Thus far a limited number of patients has received an autransplan-
tation, and up to now no relapses have been reported. It should be noted, 
however, that most patients receiving an autotransplantation suffered from 
early stage cancer when their tissue was harvested. In addition, the follow up 
period after the transplantation has been relatively short. As a consequence, 
the experience with this matter is only limited, and retransplantation of the 
malignancy can never be ruled out completely. Shaw et al. (1996) actually 
showed that lymphoma could be transmitted via cryopreserved ovarian tissue 
in a mouse model. The physician therefore has the responsibility to counsel 
the patient comprehensively on the risk of malignant cells being present in 
the ovarian tissue, and the possible consequences after autotransplantation. 
Two different approaches can be used to draft an advice.First, one can ex-
trapolate on statistical data describing the frequency with which a certain 
tumor in a certain stage will metastasize to the ovary. For a number of solid 
tumor types, ovarian metastases have been described for advanced stages 
but not for early stage tumors (Rosendahl et al., 2011). These include Hodg-
kin’s disease (Khan et al., 1986), renal cell carcinoma (Insabato et al., 2003) 
and breast cancer (Horvath et al., 1977). It should be noted, however, that 
systematically collected data are missing for most tumor types, giving only 
a limited idea of the risk of tumor dissemination to the ovary. In contrast to 
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solid tumors, diffuse malignancies such as leukemia are likely to be present 
in all blood-À lled organs, including the ovary. Therefore, patients suffering 
from these kind of diseases should probably be excluded from using (cryo-
preserved) ovarian tissue as a means of fertility preservation. The second, 
and probably preferable, option, is to tailor a patient speciÀ c approach, i.e. 
analyzing (part of) the tissue that is to be autotransplanted in the future for 
the presence of (residual) disease. In an ideal situation, sensitive and speciÀ c 
tests would be available for the detection of each tumor type in a tissue. 
Techniques that have been used to asses the presence of malignant cells in 
ovarian tissue include conventional histology (Azem et al., 2010 Donnez et 
al., 2011), immunohistochemistry (Rosendahl et al., 2011), PCR ampliÀ cation 
of tumor speciÀ c RNA/DNA (Rosendahl et al., 2010), and xenotransplantation 
of ovarian tissue fragments to immune deÀ cient mice (Dolmans et al., 2010). 
In real life, however, these approaches encounter several obstacles. Histology 
is relatively non-sensitive as individual tumor cells can be missed, and usually 
only a limited number of sections is analyzed. Whereas immunohistochemis-
try is generally more sensitive than histology, it requires speciÀ c tumor cell 
markers that are not available for most type of cancers. While PCR in itself is 
a very sensitive technique, the ratio between the few malignant cells that are 
potentially present in the graft and the large number of normal ovarian cells 
impairs the reliability and sensitivity of this test. PCR results that indicate 
the presence of residual tumor cells are therefore mostly qualitative and not 
quantitative. Furthermore, PCR detects only the presence of relatively short 
stretches of speciÀ c RNA/DNA sequences and not viable cells. Xenotransplan-
tation experiments may provide biologically relevant information, but are ex-
pensive and cumbersome and probablyl not routinely applicable. Apart from 
these practical issues, positive tests results raise some more questions. First, 
we do not know when a positive signal becomes biologically signiÀ cant, i.e. 
predictive of relapse after transplantation. Examples of this notion are a pos-
itive PCR signal that may be derived from a number of deceased cells and may 
therefore not be of clinical relevance. We currently we do not know exactly 
how many malignant cells are required for reintroduction of the tumor. In an-
imal models as few as 200 lymphoblasts were sufÀ cient to introduce leukemia 
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(Hou et al., 2007), but the same may not apply to the human situation. Next, 
the ovarian tissue fragment that is being analyzed for residual disease, is 
evidently no longer available for transplantation. The outcome of the analysis 
will therefore not necessarily be applicable to the cortical fragments that are 
actually transplanted. The importance of this notion was substantiated by 
the À nding that malignant cell DNA was found in an ovarian cortex fragment 
by PCR analysis, whereas another cortex fragment from the same ovary was 
found to be PCR-negative (Rosendahl, 2010). Finally, the autotransplantation 
of small volume cortex fragments is much less likely to reintroduce the malig-
nancy then the autotransplantation of an intact ovary. 
Concluding remarks
During the last decade the development of a number of options for fertility 
preservation for cancer patients have been seen. All the options that are cur-
rently available have their own speciÀ c indications and contraindications. The 
choice for the appropriate option will be a joint decision by both the patient 
and her physician, requiring careful evaluation and counseling. Increasing the 
awareness of physicians to address the issue of fertility preservation before 
starting gonadotoxic therapy should be an integral part of medical education.
Current research, including intact ovary cryopreservation, may lead to sever-
al exciting new options for fertility preservation. It should be noted that this 
option is not intended to replace the current possibilities, but will rather have 
its own speciÀ c patient population that may beneÀ t most from this proce-
dure. The obvious risk of intact ovary autotransplantation is reintroduction of 
the malignancy. Evidently, more research into the development of valid and 
biologically relevant tumor detection methods in ovarian tissue, as well as in 
the prevalence of ovarian metastases in cancer patients with different types 
of primary tumors, is urgently needed. 
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Abstract
Introduction
Cryopreservation and subsequent reimplantation of intact ovaries from can-
cer patients, offers potentially the best prognosis for restoring fertility after 
sterilizing cancer treatment. We used bovine ovaries as a model system to 
explore the perfusion procedure that is required for cryopreservation of in-
tact ovaries.
Methods
The arteria ovarica was cannuled, and ovaries were Á ushed with Indian ink 
for 5 min. 
Results
Successful perfusion of blood vessels was immediately visible macroscopically 
by a grey to black discoloration of the ovary and was conÀ rmed microscopical-
ly, by examining tissue sections. There was no correlation between the time 
interval of the removal of the ovary to the start of the perfusion, and success 
of perfusion. We determined the percentage of Indian ink-perfused vessels 
and scored blood vessels in four different size classes. The percentage of per-
fused vessels increased with an increase in vessel size. In a limited set of pre-
liminary experiments with human ovaries, comparable results were obtained. 
Conclusions
Our results show that bovine ovaries are a suitable and adequate model sys-
tem for optimizing the cryopreservation of human ovaries. As bovine are at 
least of comparable size to human ovaries, we expect that our results can be 
extrapolated to the human situation.
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Introduction
Over recent years, improvements in cancer therapy of cancer have lead to 
signiÀ cant increases in long-term survival rates. However, aggressive chemo-
therapy and radiotherapy can severely deplete the follicular reserve in wom-
en, often compromising ovarian function (Wallace et al., 2005). Removal, 
cryopreservation and subsequent reimplantation of ovarian tissue strips after 
cancer treatment have been successfully used to re-establish female fertility 
(Donnez et al., 2004, 2006; Meirow et al., 2005). When ovarian tissue is used 
for cryopreservation, numerous immature oocytes can be cryopreserved. Im-
mature oocytes are small, relatively quiescent and lack a zona pellucida and 
cortical granules, which makes them, in theory, more tolerant to freezing 
and thawing than mature oocytes (Kim, 2006). A major problem in ovarian 
tissue transplantation, however, is follicular loss due to ischaemic reperfusion 
injury, as assessed in both humans (Oktay and Karlikaya, 2000; Nisolle et al., 
2000) and sheep (Baird et al., 1999; Kim et al., 2004). Cryopreservation of 
an intact ovary (with vascular pedicle) for fertility preservation in cancer pa-
tients has potentially the best prognosis for restoring fertility after sterilizing 
cancer treatment. However, successful freezing and thawing of intact ovaries 
represents an immense technical challenge. Freezing of intact ovaries has 
been investigated in ovine (Bedaiwy et al., 2003; Revel et al., 2004; Courbiere 
et al., 2006; Imhof et al., 2006) and porcine (Imhof et al., 2004) animal mod-
els. These studies yielded some promising results, with regard to the number 
of surviving follicles as well as follicular function. One spontaneous pregnancy 
resulting in a live birth has been reported in sheep (Imhof et al., 2006). Re-
cently, perfusion and subsequent cryopreservation of human ovaries was de-
scribed for the À rst time (Martinez-Madrid et al., 2004; Jadoul et al., 2007).
Our objective is to optimize the technique of cryopreservation of intact ova-
ries to make it an efÀ cacious and safe procedure. As ovine ovaries are much 
smaller than human ovaries, and porcine ovaries, in contrast to human ova-
ries, have multiple follicles maturing each month, we chose bovine ovaries 
as our model system. Vessel perfusion is crucial for infusing the ovary with a 
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cryoprotectant agent as well as for reperfusion of the ovary after thawing. In 
the present study, we tested vessel perfusion in bovine ovaries, and also in 
preliminary studies in human ovaries.
Materials and Methods
Determining ovarian volume 
Bovine (n = 30), ovine (n = 31) and porcine (n = 28) ovaries from freshly 
slaughtered animals were obtained from the local abattoir and submerged in 
a vessel À lled with water. The increase in volume of the content of the vessel 
was determined and was taken to represent the volume of the ovary. Data 
from 28 human ovaries were taken from Munn et al. (1986).
Perfusion of bovine ovaries
Ovaries (n = 66) were obtained from on average 6 years old, freshly slaugh-
tered cows at a local abattoir. The phase of the ovary was determined by mac-
roscopical observation of absence (follicular phase) or presence (luteal phase) 
of a fresh (yellow/orange coloured) corpus luteum, which was always clearly 
visible after dissection of the ovary after perfusion, and the extracorporeal 
presence (follicular phase) or absence (luteal phase) of cervical mucus. As we 
had no inÁ uence on the choice of the animals to be slaughtered, we decided 
to perfuse all ovaries we received, independent of the phase they were in. 
The arteria ovarica in the vascular pedicle was prepared; the vessel (inner 
diameter 0.8 –1.2 mm) was transected 10 cm under the ovarian hilus. Next, 
a canule (18 GA 1.77, 1.3 – 3.5 mm VenÁ on) was inserted into the vessel and 
secured with sutures. The canule was connected with an Original perfusion 
Hiose (Braun, Melsungen, Germany) to a peristaltic STC-521 Seringe pump 
(Terufusion, Tokyo, Japan). Perfusion rate was set at 2.5 ml/min as described 
by Martinez-Madrid et al. (2004). Vessels branching of from the A. ovarica that 
became visible during perfusion with Indian ink were ligated during the proce-
dure. After perfusion, ovaries were À xed in buffered formalin for subsequent 
histological examination. The ovaries (n ¼ 66) were perfused with a solution 
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of 25% Indian ink/167 IU heparin in 0.9% NaCl for 5 min. The elapsed time be-
tween the death of the cow and start of the perfusion varied between 30 and 
240 min, with 30 min being the shortest interval that was practically possible. 
A perfusion was considered to be successful if Indian ink was seen to perfuse 
the ovary macroscopically (black discolouration of tissue and follicles), the 
peristaltic pump did not shut down due to increased intravascular pressure 
and outÁ ow of Indian ink was observed in the venous plexus of the artery.
Immunohistochemical staining of blood vessels
As no antibodies against bovine endothelial cells were available, a panel of 
antibodies directed at different vascular components (human CD34, Factor 
VIII, laminin and collagen IV) was tested to determine the optimal staining for 
highlighting bovine blood vessels.
After À xation, sections of ovaries were embedded in parafÀ n. BrieÁ y, 4 mm 
sections were deparafÀ nized with xylol for 10 min, and endogenous perox-
idase activity was blocked by incubation for 30 min in 10% H2O2 diluted in 
phosphate-buffered saline (PBS) solution.
Next, sections were washed in PBS, incubated for 10 min with protease 
14 (Sigma, St Louis, USA) at 378C for 10 min to unmask the antigens and 
epitopes. After washing in PBS, sections were incubated at room tempera-
ture with 20% normal goat serum (anti-factor VIII and anti-laminin) or nor-
mal horse serum (anti-collagen IV and anti-CD34) (Vector, Burlingame, USA) 
diluted in PBS for 10 min. Subsequently sections were incubated overnight 
at 48C with polyclonal rabbit-anti-human von Willebrand factor VIII antibody 
(CLB, Amsterdam, the Netherlands) diluted 1:600 in PBS with 1% bovine serum 
albumin (BSA), polyclonal goat-anti-laminin antibody (Dako, Glostrup, Den-
mark, dilution 1:4000), horse-anti-mouse collagen IV antibody (Sigma-Aldrich, 
St Louis, USA), or monoclonal mouseanti-human CD34 antibody (Labvision/
Neomarkers, Fremont, USA diluted 1:750). After washing in PBS for 15 min, 
sections were incubated for 30 min with either (depending on the primary 
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antibody) antirabbit IgG, (diluted 1:200 in PBS/1% BSA), anti-goat (diluted 
1:200), anti-horse (diluted 1:200) or anti-mouse IgG (1:200) all conjugated 
to biotin, respectively (Vector). After washing in PBS for 15 min, sections 
were incubated at room temperature for 45 min with peroxidaseconjugated 
avidin–biotin complex (Vectastain ABC-kit, Vector, Burlingame, USA) diluted 
1:50 in PBS/1% BSA. Finally, sections were incubated with AEC (SKY Tek) 1:50 
diluted in AEC Buffer (SKY Tek, Logan, USA), counterstained for 1 min with 
hematoxylin, dehydrated with Imsol (Klinipath, Duiven, the Netherlands) and 
mounted with permount (Fisher, NJ, USA). Tissue sections were analysed by 
conventional light microscopy.
Determination of percentage of perfused vessels
Numbers of perfused and non-perfused (as determined by the presence and 
absence of Indian ink in the vessel lumina, respectively) blood vessels were 
counted in 11 ovaries, which were randomly selected from the 34 success-
ful perfusions we performed, making sure to include different time intervals 
between death of the animal and start of the perfusion in the series that 
was histogically analysed. We counted the vessels in À ve À elds per section of 
stromal tissue, and À ve À elds of perifollicular tissue, at a magniÀ cation of x 
100 (arterioles and venules, medium sized and large vessels, see Fig. 2), or 
x 400 (capillaries). Mean perfused vessel number per high-powered À eld was 
calculated for the vessel classes mentioned above, and mean vessel numbers 
were statistically analysed using Mann–Whitney U-test. 
Perfusion and staining of human ovaries
Human ovaries were obtained from a 42-year-old woman and from a 38-year-
old woman, who had bilateral ovariectomies as a consequence of the pres-
ence of a hormone susceptible breast tumour, and of being a carrier of a 
BRCA-1 gene mutation, respectively. Approval for the procedure was obtained 
from the local ethical committee, provided the procedure would not interfere 
with the necessary diagnostic histology. The vascular pedicle was prepared 
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and an 18 GA 1.77, 1.3 x 35 mm canule (VenÁ on) was inserted in the arteria 
ovarica. The ovaries were perfused for 5 min with an Indian ink/heparin solu-
tion as described for the bovine ovaries. After perfusion, ovaries were À xed, 
and an anti-CD34 immunohistochemical staining to highlight blood vessels was 
performed as described for bovine ovaries.
Results
Choice of bovine ovaries as a model system
We decided that the species providing the ovaries for our model system had to 
encompass the following properties: monthly rather than yearly ovulation and 
a maximum of two maturing follicles each month. Sheep ovulate only once 
or twice a year, whereas in porcine ovaries, multiple follicles mature each 
month. In addition, we decided that the ovaries of the test species should be 
at least as large, or larger, as human ovaries. Ovarian volumes from different 
species were determined or derived from literature (Fig. 1). With a volume 
of 6.5 ± 2.9 cm3 (mean ± SD) (Munn et al., 1986) human ovaries are compa-
rable in volume to porcine (7.3 ± 2.2 cm3) ovaries, whereas bovine and ovine 
ovaries are considerably larger (14.3 ± 5.7 cm3), and smaller (1.0 ± 0.4 cm3), 
respectively. Taking together these considerations, we decided to select bo-
vine ovaries as our model system for subsequent experiment.
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Figure 1: Ovarian volumes of different species. Volumes of bovine, porcine
and ovine ovaries were determined experimentally. Each solidcircle repre-
sents an individial measurement, and mean volumes ±SD are indicated. In 
the right hand column, volumes of human ovaries as derived from literature 
(Munn et al 1986) are presented, depicted as mean ±SD. Open squares indi-
cate the range of the measurements, representing the minimum and maxi-
mum volume.
Determination of optimal conditions for macroscopically 
successful perfusion
In clinical practice, perfusion of the ovary to be cryopreserved will not al-
ways be feasible within a short period after removal. Therefore, we varied 
the time between death of the cow, i.e. stopping of ovarian circulation, and 
start of the perfusion procedure with the Indian ink/heparin solution. We 
considered perfusion to be successful when we observed complete blackening 
of the tissue after perfusing the ovary for 5 min (Fig. 2). Already 3 min af-
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ter start of the perfusion, the afferent arterioles started to blacken, clearly 
demonstrating that a vascular plexus rather than a limited number of arteries 
is responsible for the ovarian blood supply. A slight darkening of the ovarian 
tissue was observed as well (Fig. 2b). Five minutes after start of the perfu-
sion, the blackening of both the vascular plexus and the ovarian tissue was 
more distinct (Fig. 2c). After dissection, the grey to black appearance of the 
ovarian tissue indicated complete perfusion of the ovary (Fig. 2d).
Figure 2: Perfusion of bovine ovary with an Indian ink/heparin solution
(a) At start of perfusion; (b) 3 min after start of perfusion; (c) 5 min after 
start of perfusion; (d) after perfusion: ovary after transversal dissection. 
Note extensive blackening of the tissue after perfusion. F, follicle
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Elapsed time (min) 
between removal of 
ovary and start of 
perfusion
30
45
60
 120
Total
Perfused fraction (99% CI)
Successful perfusion 
per total number of 
perfusions of ovaries 
in follicular phase
8/10
8/10
8/10
3/4
7/34
0.79 (0.57–0.92)
Successful perfusion per 
total number of perfu-
sions of ovaries in luteal 
phase
2/10
2/10
2/10
1/2
7/32
0.22 (0.08–0.45)
Table I. Success of perfusion with Indian ink/heparin solution at different 
time points after removal of the ovary.
Table I shows the results of the perfusion procedure at different time points 
after stopping the ovarian circulation. Perfusion was successful most of the 
time (80%) when the perfusion was started soon after stopping the ovarian 
circulation (up to 60 min). To our surprise, however, perfusion was still feasi-
ble 2 and even 4 h after removal of the ovary. Crucial for successful perfusion 
after more than 60 min, however, was insertion of the canule in the afferent 
vessel (arteria ovarica), as soon as possible after obtaining the ovary. When 
data obtained at different time points were pooled, the successful perfusion 
rate was signiÀ cantly higher with ovaries in the follicular phase (27 out 34) 
than with ovaries in the luteal phase (7 out of 32, P< 0.01). Optimal perfusion 
of the ovary with cryoprotectant may require a perfusion period of more than 
5 min. Therefore, we examined the effect of increasing the perfusion time 
with Indian ink/heparin to 15 or 30 min. After 15 min, we observed an in-
creased pressure in the tissue, as indicated by shutdown of the peristaltic 
pump and swelling of the tissue. Vascular leakage and tissue damage was in-
dicated by release of Indian ink throughout the tissue. Our results indicated 
that no additional perfusion occurred when the perfusion period exceeded 5 
min.
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Immunohistochemical determination of vessel perfusion in bovine ovary
To further analyse the results of the perfusion experiments with Indian ink, 
we performed immunohistochemical analysis of tissue sections. BrieÁ y, en-
dothelial cells in tissue sections of perfused ovaries were stained with an-
ti-endothelial cell antibodies to highlight all blood vessels. Next, we scored 
the total number of stained blood vessels, and determined the percentage of 
blood vessels containing Indian ink, for different size classes of vessels.
Figure 3: Tissue section of bovine ovary perfused with Indian ink/hep-
arine, and stained with anti Factor VIII antibody to highlight endothelial 
cells (red). Note presence of Indian ink (black) in lumen of blood vessels. 
MagniÀ cation x 100. Size classes of counted blood vessels, ranging from 
capillaries, arterioles and venules, medium sized vessels and large vessels, 
areindicated. Capillaries, black arrow; arterioles and venules, open arrow; 
medium sized vessels, black arrowhead; large vessels, open arrowhead 
We tested a panel of antibodies directed against different vascular compo-
nents. Only the anti-factor VIII antibody resulted in satisfactory staining of 
blood vessels and was therefore used for further analysis (data not shown). 
Fig. 3 shows a tissue section of perfused ovary, stained with anti-Factor VIII. 
Our data show that the Indian ink was contained within the blood vessels and 
was not observed in the surrounding tissue. We scored blood vessels in four 
different size classes, ranging from capillaries to very large afferent and ef-
ferent vessels, both in the cortex (perifollicular vessels) and in the medulla 
(stromal vessels).
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Figure 4: Percentage of Indian ink containing vessels in relation to vessel 
size. (a) Stromal vessels (medulla); (b) perifollicular vessels (cortex). Each 
dot represents the percentage of perfused vessels of a single ovary (n=11). 
NS, not signiÀ cant; *, 0.05 > P > 0.01; **, P< 0.01
Optimal perfusion of an intact ovary 
as a prerequisite for successful ovarian cryopreservation
61
The percentage of perfused vessels increased, with an increase in vessel size 
(Fig. 4). As indicated in Fig. 4, this increase was statistically signiÀ cant in 
a number of instances. Whereas in the medulla (Fig. 4a) only 16% of the 
capillaries were perfused, this percentage increased to 37, 65 and 62% in 
arterioles and venules, medium sized vesels and large vessels, respectively. 
In the cortex (Fig. 4b), percentages of perfused vessels were 15, 32, 63 and 
62%, respectively. There was no statistical difference in the percentage of 
perfused vessels in the ovarian medulla compared with vessels in the cortex 
(data not shown).
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Perfusion of human ovaries with Indian ink
We perfused two human ovaries with Indian ink to investigate whether we 
could extrapolate our bovine data to the human situation.
Although canulation of the afferent vessel was more difÀ cult than with bovine 
ovaria, we were able to successfully perfuse one of the ovaries of each wom-
an (the other ovary was used for diagnostic purposes). Tissue sections of the 
successfully perfused ovary were stained with anti-CD34 antibody to highlight 
blood vessels (Fig. 5). Analogous to our bovine data, we observed the pres-
ence of Indian ink mainly in the larger vessels, whereas capillaries hardly ever 
contained ink. Again, tissue damage as a result of the perfusion process was 
not observed, as indicated by the absence of Indian ink in the stromal tissue.
Figure 5: Tissue section of human ovary perfused with Indian ink/heparin, 
and stained with anti-CD34 antibodies to highlight bloodvessels. Note the 
presence of Indian ink in larger bloodvessels, but not in capillaries. MagniÀ -
cation x200
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Discussion
To date, IVF procedures before cancer therapy to produce embryos that can 
be transferred in a later stage of life can be employed to preserve fertility 
in women with cancer who are subjected to a fertility threatening therapeu-
tical intervention. Recently, cryopreservation followed by transplantation of 
cortical ovarian strips has been employed to establish pregnancies in cured 
cancer patients. Both options are limited, since the number of embryos that 
can be produced, as well as the life expectancy of reimplanted cortical strips, 
is restricted. Obviously, the fact that generally a number of ovarian strips 
are cryopreserved implies that several attempts at fertility restoration can 
be undertaken. In addition, a stable relationship between the patient and 
her partner must have been established for IVF to be an option. Cryopreser-
vation and subsequent reimplantation of total ovaries may therefore in se-
lected cases be an alternative option for fertility preservation, as all options 
are re-established by this procedure. If successful, revascularization of the 
retransplanted ovary not only results in prolonged survival of the graft, but, 
as result of decreased ischaemia in the ovarian tissue, leads to an increase 
in the number of surviving follicles. Of course, as with transplantation of 
cortical strips, extreme caution should be taken to prevent reintroduction 
of the tumour. Transplantation of total ovaries that had been cryopreserved 
leading to a pregnancy and live birth in sheep has been reported by Imhof et 
al. (2006). This À nding indicates that an analogous therapy in humans is, at 
least theoretically, feasible, although one should bear in mind that ovine ova-
ries are much smaller than human ovaries (this paper), and will therefore be 
much easier to successfully freeze and thaw. The same authors showed that 
perfusion of porcine ovaries with DMSO as a cryoprotective agent, resulted in 
improved protection from damage induced by the cryopreservation process, 
compared with only submerging the ovary in the cryoprotective solution (Im-
hof et al., 2004). Extrapolating on this À nding, we expect that perfusion of 
bovine and human ovaries with cryoprotective agent will be more effective 
in supplying protection, as already shown by Martinez-Madrid et al. (2004). In 
addition, perfusing the ovary via its afferent vessel may increase the survival 
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and condition of the ovarian blood vessels which are crucial for successful 
reperfusion after transplantation (Martinez-Madrid et al., 2007). In our Indian 
ink perfusion studies, we observed that especially the larger vessels were well 
perfused, whereas the smaller vessels and the capillaries, via which extrav-
asation of the cryoprotective Á uids will occur most prominently, were less 
well perfused. On the other hand, the relatively smaller molecular weights of 
cryoprotective agents such as DMSO and sucrose imply that they would be less 
subject to molecular À ltering mechanisms by endothelial cells and basal mem-
branes. We therefore assume that these will also enter the tissue from larger 
vessels, although we have no experimental data to support this assumption. 
In addition, even if 16% of capillaries and 37% of arterioles are perfused, this 
may still result in sufÀ cient dispersion of the cryoprotective agent. We are 
currently performing perfusion studies with Á uorescently labelled molecules 
to assess the tissue saturation with the cryoprotective perfusion Á uid. As an 
alternative, one may consider injecting the ovarian tissue with cryoprotective 
agents in order to ensure a more complete saturation of the tissue. However, 
as this procedure may result in tissue damage, this is, in our opinion, not 
the option of choice. Martinez-Madrid et al. (2007) have described the fol-
licular survival in cryopreserved and subsequently thawed complete human 
ovaries that were perfused with, and frozen in, a solution containing DMSO 
as a cryoprotective agent. Remarkably, 75% of follicles survived the freeze/
thaw cycle, indicating that the crucial structures in the ovary are more robust 
than one would expect. Conceivably, more follicles are lost due to ischaemic 
conditions after retransplantation of ovarian tissue than by the process of 
cryopreservation. Proof of concept, however, will be the assessment of follic-
ular survival after the transplantation and the in vivo reperfusion and revas-
cularization of the ovary. In addition, the long-term toxic effects of remnants 
of the cryoprotective agent in which the ovary has been frozen, which may 
remain in the tissue even after Á ushing with saline, will have to be evaluated. 
To date, no data have been published on the optimal freezing and thawing 
procedure for intact human ovaries. In this study, we have performed exper-
iments that may be indicative for properly performing the initial stage (per-
fusion) of the procedure for freezing intact ovaries, using animal ovaries as a 
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model system. For a suitable model system, (i) the ovaries should be at least 
comparable in size with human ovaries; (ii) only one or two follicles should 
mature each cycle as the maturation of multiple follicles greatly inÁ uences 
the ovarian volume and therefore the outcome of the freezing process and 
(iii) the animal of choice should have a monthly cycle. We considered bovine, 
porcine and ovine ovaries as possible candidates for our model system. Vol-
ume measurements indicated that whereas porcine ovaries are comparable in 
size to human ovaries, bovine ovaries are considerably larger and ovine ova-
ries are much smaller. However, in pigs multiple follicles mature each cycle, 
possibly resulting in a different architecture and/or vasculature of the ovaries 
compared with ovaries in which only one or two follicles mature each month. 
Therefore, we selected bovine ovaries as our model system. The larger size of 
the bovine ovaries may actually be an advantage in extrapolating our results 
to the human situation. If we succeed in successful cryopreservation of large 
bovine ovaries, the chances are that attempts at cryopreservation of the rel-
atively smaller human ovaries will be successful as well.
We assessed several parameters that determine the efÀ cacy of the perfusion 
process. Applying pressure on the vasculature of the ovarian tissue by the per-
fusion pump may result in vessel rupture and tissue damage. Our histological 
data have shown that after 5 min of perfusion, the Indian ink was completely 
contained within the blood vessels, and no tissue damage was visible. Ob-
viously, the time between removal of the ovary, and start of the perfusion 
process and the cryopreservation should be minimized as much as possible, 
to prevent ischaemic damage to the ovary. We have shown that successful 
perfusion is possible as long as 4 h after removal of the ovary. After 4 h, 
perfusion was no longer possible, probably due to intravascular coagulation. 
In addition, we have shown that a perfusion time of 5 min sufÀ ces to per-
fuse the majority of the larger vessels. It should be noted, however, that we 
could not exclude the possibility that we underestimated the total number of 
blood vessels. In human tissues, it is well established that the anti-factor VIII 
antibody does not stain all blood vessels, and the same phenomenon may be 
occurring in our bovine ovaries. As a consequence, the percentage of perfused 
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vessels we observed may in reality be lower. Our preliminary data indicate 
that perfusion via this protocol results in a satisfactory perfusion of human 
ovaries as well. We observed a statistically signiÀ cant (P , 0.01) higher success 
rate of the perfusion process in ovaries in the follicular phase compared with 
ovaries in the luteal phase. This may be explained by the fact that, at least in 
humans, ovaries in the follicular phase are better vascularized than ovaries in 
the luteal phase (Jokubkiene et al., 2006).
Usually perfusion prior to cryopreservation of tissue is performed at tem-
peratures between 0 and 4°C, whereas we performed our experiments at 
about 12–15°C. In addition, the perfusion characteristics from DMSO, sucrose 
or other cryoprotective agents may differ from that of the Indian ink solution 
we employed. In future experiments, we intend to address these matters.
In conclusion, our study has provided the À rst experimental data in deter-
mining the À rst stage of the optimal procedure to cryopreserve intact human 
ovaries. In a next set of experiments, we intend to investigate the diffusion 
time of small molecular weight molecules such as cryoprotectants into the 
tissue after perfusion and to determine whether a longer perfusion time may 
increase the saturation of the tissue with the cryoprotectant. In addition, we 
intend to study the effects of different types of cryoprotective agents on the 
functional survival of the ovarian tissue.
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Abstract
Transplantation of cryopreserved intact ovaries from cancer patients is a 
technically challenging option for restoring fertility after sterilizing cancer 
therapy. In this paper we describe an assay based on 17ß-oestradiol (oestra-
diol) production, to monitor the functional damage sustained by the ovarian 
tissue during the freeze/thawing procedure. To this end, fresh bovine ovarian 
cortical biopsies were cultured in vitro for 7 days. As a control, the oestradiol 
release of biopsies that had sustained maximal cryodamage was analyzed. In 
addition the oestradiol release by cortical biopsies from two ME²SO perfused 
and cryopreserved intact ovaries were analyzed. Oestradiol production could 
be measured in culture supernatants, while oestradiol release of maximal 
cryo-damaged biopsies was at background levels. In vitro oestradiol release 
by cortical biopsies can be used as a functional marker for cryo-damage and 
indicates that our assay is suitable to optimize the cryopreservation proce-
dure of intact ovaries.
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Introduction
New protocols in the early diagnosis and treatment of cancer have led to ma-
jor improvements in the long-term survival of oncological patients. However 
treatment of cancer with aggressive chemotherapy, especially when using 
alkylating agents and/or radiotherapy of the pelvic region, often leads to in-
fertility, due to the damage of the follicles and/or oocytes that are present in 
the ovaries (Wallace, Anderson et al., 2005). Safeguarding their reproductive 
potential is a very important issue for women that have not yet started or 
completed their family. 
Several options, including ovarian tissue cryopreservation and transplanta-
tion, can now be offered to these women to (partially) preserve their fertility. 
New experimental approaches using in vitro growth of isolated human folli-
cles are also explored (Dolmans, Martinez-Madrid et al., 2007;Dolmans, Yuan 
et al., 2008;Sadeu and Smitz, 2008).
Ovarian tissue can be frozen and grafted as cortical fragments, or as an in-
tact ovary including its vascular pedicle (Donnez, Dolmans et al., 2004). The 
cryobiological and surgical aspects of the preservation and transplantation of 
an organ in toto, is technically clearly more challenging than the cryopres-
ervation and transfer of cortical fragments. The advantages of this approach 
are obvious; immediate revascularization of the transplanted ovary ensures 
that less ischemic damage will be inÁ icted to the ovarian tissue post-thawing, 
and that more follicles are likely to survive. In addition menses, normal re-
productive functions, and normal hormonal status can be restored (Bedaiwy, 
Jeremias et al., 2003).
In the last few years, freezing and autologous grafting of whole ovaries has 
been attempted in several mammalian species, including rats (Wang, Chen 
et al., 2002;Yin, Wang et al., 2003), rabbits (Chen, Chen et al., 2006), pigs 
(Imhof, Hofstetter et al., 2004;Imhof, Bergmeister et al., 2006), and sheep 
(Arav, Revel et al., 2005;Bedaiwy, Jeremias et al., 2003;Courbiere, Massar-
dier et al., 2005;Imhof, Bergmeister et al., 2006;Revel, Elami et al., 2004), 
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yielding promising results. In sheep, this procedure has even resulted in live 
offspring (Imhof, Bergmeister et al., 2006). However, it should be kept in 
mind that ovine ovaries are considerably smaller than human ovaries (Ger-
ritse, Beerendonk et al., 2008). Therefore, it remains to be seen whether 
cryopreservation of larger intact organs such as human ovaries can be per-
formed equally successful, as volume has a considerable effect on parame-
ters that affect successful cryopreservation. Although cryopreservation of an 
intact human ovary with its vascular pedicle has been described (Bedaiwy, 
Hussein et al., 2006a;Martinez-Madrid, Dolmans et al., 2004), transplantation 
of a cryopreserved and thawed ovary has not yet been reported. Ideally, the 
optimal cryopreservation procedure, which obviously requires an assay that is 
able to detect cryo injury to preantral follicles, should be determined before 
cryopreservation and transplantation of human ovaries can be efÀ ciently per-
formed. In this paper, we used our previously described model system (Gerri-
tse, Beerendonk et al., 2008) employing bovine ovaries, to develop a suitable 
monitoring system for follicular survival after cryopreservation. Follicular sur-
vival in previous studies has been assessed predominantly by using cell based 
assays such as trypan blue exclusion, apoptosis assays, immunohistochemistry 
and conventional histology. The outcome of these assays has demonstrated a 
high percentage of viable follicles after cryopreservation (Martinez-Madrid, 
Camboni et al., 2007b). Whether these results represent functional follicular 
survival is not clear. In addition, follicular survival was analyzed directly af-
ter thawing of the tissue (Martinez-Madrid, Camboni et al., 2007b), whereas 
for instance apoptosis may take several hours to become manifest (Hussein, 
Bedaiwy et al., 2006;Yang, Lee et al., 2008). For this reason, we argued that 
an assay that speciÀ cally monitors functional follicular survival for several 
days after thawing of the ovarian tissue is a prerequisite for optimizing the 
cryopreservation process. Ideally, this assay should monitor the survival of 
primordial and primary follicles, as these are needed for replenishing the pool 
of developing follicles after retransplantation. On the other hand, secondary 
and antral follicles have been shown to be more prone to cryodamage, due 
to the fact that they are metabolically active, and contain Á uid that may, by 
the formation of ice crystals, increase the induction of cryodamage (Gosden, 
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2002). Monitoring the survival of the latter subsets of follicles may therefore 
be a more sensitive assay for determining cryodamage sustained during the 
cryopreservation process. We therefore studied the production of 17ß-oestra-
diol, as this is produced exclusively by viable secondary and antral follicles 
(Abir, Biron-Shental et al., 2009). Production of oestradiol by cortical biopsies 
in vitro was monitored during a culture period of 7 days. We show that oes-
tradiol is produced de novo by cortical biopsies, and is related to the amount 
of cryo damage that is induced in an intact ovary by cryopreservation. There-
fore, we consider this assay to be a valuable addition to the current array of 
techniques that are available to optimize the cryopreservation procedure of 
intact human ovaries.
Materials And Methods
Tissue collection 
Ovaries were obtained from freshly slaughtered adult cows at a local abattoir, 
as described previously (Gerritse, Beerendonk et al., 2008). Ovaries that were 
used for direct culturing of biopsies were collected on ice and transferred to 
the laboratory for further preparation. Ovaries that were used for cryopres-
ervation in toto were perfused with 15 ml of a PBS/heparin (50 IE/ml, Leoph-
arm, Breda, The Netherlands) solution via the vena ovarica that was transact-
ed approximately 10 cm under the ovarian hilus. Vessels branching from this 
vein were occluded using sutures. After perfusion ovaries were placed on ice 
and transferred to the laboratory within 30 min.
Cortical biopsy preparation and culturing
Ovarian biopsies were collected from 15 different ovaries, derived from 15 
individual animals. Each ovary corresponds to a separate experiment. Only 
areas free from visible follicles were used to obtain biopsies. Using a biopsy 
punch and scissors, biopsies with a diameter of 6 mm and an approximate 
depth of 2 mm were obtained. Biopsies were transferred to 6-well plates (Fal-
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con, Heidelberg, Germany) for culturing. For each ovary duplicate wells were 
prepared, each of which containing 3 fresh biopsies in 5 ml of culture medium 
(DMEM supplemented with 10% FCS, 100IU per ml of penicillin and 0.1 mg per 
ml of streptomycin). After 4 days, culture medium was collected and fresh 
medium was added to the wells. In some experiments, biopsies were cultured 
in the presence of 2 U/ml urinary human FSH and 2 U/ml LH (Menopur, Fer-
ring, Hoofddorp, the Netherlands). In addition, fresh biopsies were collected 
in a cryovial (Nunc, Roskilde, Denmark), and subjected to maximal cryo injury 
by 3 cycles of freezing and thawing by alternate incubation in liquid nitrogen 
and 37 °C for 5 minutes each. Next, biopsies were cultured in 5 ml of medi-
um as described for fresh biopsies. Culture supernatants were analysed for 
oestradiol at day 4 and day 7.
Oestradiol levels in culture supernatants
Oestradiol was measured by radioimmunoassay after extraction and Sepha-
dex-20 chromatography (Thomas, Corbey et al., 1977). The sensitivity of the 
assay was 10 pmol/l. The within-assay coefÀ cient of variation was 4.9% at a 
level of 510 pmol/l. The between-assay coefÀ cient of variation of the mean 
of duplicate measurements was 5.6%.
Cryopreservation and thawing of intact ovaries
Ovaries were immersed in a bath containing 25 ml of the cryoprotective solu-
tion (10% dimethylsulphoxide (ME²SO) in DMEM supplemented with 2% FCS) 
and perfused with this same solution using a peristaltic STC-521 Syringe pump 
(Terufusion, Tokyo, Japan) at a Á ow rate of 2.5 ml/min for 5 min (Martin-
ez-Madrid, Dolmans et al., 2004). After perfusion ovaries were transferred to 
a 5100 Cryo Freezing Container (Nalgene, VWR, Belgium) containing 2-pro-
panol, precooled at 4°C. The container was stored at -80°C overnight, al-
lowing for a gradual decrease in temperature. Subsequently, the cryovial was 
stored in liquid nitrogen for at least 1 week. Ovaries were thawed at 60°C for 
10 min, followed by an additional incubation at 37°C for 20 min. After thaw-
ing, the ovaries were removed from the cryovial, and submerged in 25 ml of 
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DMEM. The cryoprotectant was gradually removed by 3 consecutive perfusion 
steps for 10 min at room temperature at a Á ow rate of 2.5 ml/min using DMEM 
with 0.25 M sucrose, DMEM with 0.1 M sucrose and DMEM without sucrose, 
respectively. Biopsies from cryopreserved/thawed ovaries were prepared and 
cultured as described for fresh ovaries.
Histochemical staining of follicles
Sections of ovaries were À xed O/N in phosphate buffered 4% formaldehyde, 
and embedded in parafÀ n. Five m sections were stained with Azan trichrome 
histological staining, a staining method that highlights connective tissue in 
darkblue, whereas cellular nuclei are stained bright red. Tissue sections were 
analysed by conventional light microscopy (x100) and photographed.
Ovarian biopsy lysates
Per ovary, 3 snap frozen fresh (non-cultured) biopsies were pulverized by 
using either a pestle and mortar (5 ovaries) or by using a Mikro-Dismembrator 
II (4 ovaries) (Braun Biotech, Melsungen, Germany). Each ovary was derived 
from a separate animal. To allow for direct comparison with the results from 
cultures with intact tissue biopsies, 5 ml of medium was added to the pulver-
ized samples, and oestradiol was allowed to diffuse into the culture medium 
overnight. Subsequently, supernatants were analyzed for oestradiol content.
Statistical
Data were tested for normality using GraphPad Prism version 4.00 for Win-
dows, GraphPad Software, San Diego California USA, www.graphpad.com, and 
found to be normal. Two-sided Student’s t-test was performed using the same 
software package.
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Results
Oestradiol release by cultured ovarian biopsies
We evaluated the usefulness of oestradiol release as a marker for follicular vi-
ability before and after sustained cryo-injury. Duplicate sets of three cortical 
biopsies were cultured in vitro for 4 or 7 days, after which oestradiol levels 
in the culture supernatant were assessed. To induce maximal cryo-damage 
(MCD), additional sets of biopsies from the same ovary were subjected to 
three freeze/thaw cycles before culturing. A representative experiment is 
shown in À gure 1. 
Figure 1: In vitro oestradiol release (duplicate measurements) by bovine 
cortical ovarian biopsies. Solid bars: viable biopsies; open bars: biopsies 
frozen and thawed 3 times to induce maximally cryo-damage. Oestradiol lev-
els in culture medium were assessed after 0-4 days and 5-7 days of culture. 
Total release (day 0-7) isrepresented in the right handset of columns.
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After 4 days of culture, oestradiol levels derived from vital biopsies were well 
above background levels (duplicate measurements of 1030 and 2080 pmol/L 
versus a mean level of 18 pmol/L in 5 separate unconditioned medium sam-
ples). Oestradiol release decreased considerably during the subsequent cul-
ture period (day 5-7). In a separate experiment, biopsies were cultured in 
medium containing a mixture of human FSH/LH. This FSH/LH treatment did 
not affect oestradiol production by the cortical biopsies (data not shown). 
MCD samples released considerably less oestradiol (136 and 75 pmol/L for a 
duplicate measurement), but still higher than the medium control level. Cu-
mulative oestradiol release during the entire 7 day culture period was approx-
imately 20 times higher for vital biopsies compared to MCD-biopsies, indicat-
ing that cryo-damage of ovarian tissue signiÀ cantly impairs oestradiol release.
Extensive growth of adherent À broblast-like cells was observed during the 
culture of the cortical biopsies. Generally, 50 % of the surface of the culture 
well was covered with these cells after 7 days of culture. This cell growth was 
never observed in wells containing MCD biopsies, conÀ rming that presumably 
no living cells were present in these biopsies anymore. To assess the possible 
contributions of these adherent cells to the measured oestradiol levels, we 
removed the cortical biopsies from a number of wells, and added fresh cul-
ture medium to these wells (without biopsies). After an additional 4 day cul-
ture period, oestradiol levels were determined in the medium conditioned by 
the adherent cells, and found to be below the detection level of the oestra-
diol assay (comparable to fresh medium, data not shown).
As can be observed in À gure 1, the difference between the duplicate oestra-
diol measurements was quite substantial. In the next set of experiments, we 
therefore analysed the intra- and inter-ovarian variation in oestradiol release 
in more detail. 
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Intra- and inter-ovarian variation in oestradiol release
In a set of 15 ovaries derived from 15 individual animals, we compared the 
differences between duplicate oestradiol measurements to assess intra-ovary 
variation (À gure 2a). Results are expressed as the fold difference between the 
duplicates. When both measurements are equal, this results in a fold differ-
ence of 1.0. Oestradiol levels were determined after culture periods of 0-4 
days and 5-7 days, for both vital biopsies and MCD-biopsies.
The intra-ovary variation in oestradiol release between days 0-4 ranged be-
tween 1.1 and 3.5, with a mean of about 1.8. The variation appeared to 
diminish during the 5-7 days culture period, with a range of 1.0 and 2.3 and 
a mean of 1.5, but was not statistically different from the variation observed 
at the day 0-4 period. Obviously, the variation observed in the cumulative 
oestradiol release (day 0-7) was intermediate (ranges 1.0-2.7, mean 1.7). 
Variation in oestradiol release from MCD samples was generally lower than 
the variation found with vital biopsies, but no signiÀ cant differences were 
observed. No inÁ uence of the phase of the ovary on the level of variation was 
observed.
Inter-ovary variation was analysed by comparing the mean of duplicate meas-
urements derived from biopsies obtained from the same 15 ovaries, expressed 
as absolute oestradiol levels (À gure 2b). The same parameters as mentioned 
in the previous section were analysed. A similar pattern in variability was 
observed as in the intra-ovary variation; variation was clearly lower in the 
5-7 day culture period (range 200-905, mean 601 pmol/L) compared to the 
0-4 day period (range 305-1750, mean 1015 pmol/L), and variation in MCD 
samples was lower compared to vital samples (range 135-338 with mean 235, 
and range 505-2655 with mean 1755 pmol/L, respectively, in cumulative day 
0-7 samples). Based on morphological criteria (clear absence or presence of 
a corpus luteum), the phase of the ovaries could be assigned unambiguously 
in 10 out of 15 ovaries. In general, ovaries in the luteal phase produced more 
E2 than ovaries in the follicular phase. This difference was actually statis-
tically different (p=0.02, 0.01 and 0.01 at culture periods 0-4, 5-7 and 0-7, 
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respectively). Statistical analysis of the effect of the maximum cryo-damage 
inducing procedure on the level of oestradiol release (À gure 2b), showed a 
highly signiÀ cant decrease compared to fresh biopsies. This decrease was ap-
parent in the day 0-4 samples (p<0.001) , the day 5-7 samples (p<0.0001), as 
well as in the 0-7 samples (p<0.0001). This À nding, together with the lack of 
outgrowth of À broblast-like cells from MCD-biopsies, indicates that the MCD 
procedure indeed results in non-viable tissue.
Figure 2: Assessment of intra- and inter- ovary variation of in vitro oes-
tradiol release by ovarian biopsies, derived from fi fteen ovaries, each 
from a separate animal. Each circle (fresh tissue) or triangle (tissue with 
maximal cryo damage, MCD) represents a single ovary. Circles with a hori-
zontal bar represent ovaries in luteal phase, with vertical bar ovaries in fol-
licular phase, open circles represent ovaries of unknown phase. Mean values 
are indicated by horizontal lines. (a) Intra-ovary variation is expressed as 
fold-difference between duplicate oestradiol levels in culture medium of bi-
opsies derived from an indidual ovary. (b) Inter-ovary variation is represent-
ed by the absolute levels (pmol/L) of oestradiol relase by different ovaries, 
expressed as mean of a duplicate measurement for each ovary.
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Distribution of follicles in bovine ovarian tissue
To explain the observed intra- and interovary variation in in vitro oestradiol 
release by ovarian biopsies, we investigated the distribution of follicles in 
histological sections of four separate ovaries. Sections were stained in order 
to highlight follicular structures (À gure 3). As highlighted by the intense blue 
staining, the sub-epidermal part of the cortex is rich in extracellular matrix 
components. Follicles (oocytes stained red, surrounded by granulosa cells; 
indicated with white arrowheads in À gure 3a and b, and shown in more detail 
in À gure 3c), are oriented beneath this layer. As can be seen in À gure 3 a and b 
(representing different areas of the same ovary) the distribution of follicles in 
the ovarian cortex was not random, but clustered. As a consequence, biopsies 
that are taken randomly may contain different numbers of follicles, rang-
ing from several dozens to none at all. This will obviously affect subsequent 
oestradiol release by the biopsies.
Figure 3: Tissue sections of bovine ovaries were stained using the Azan 
protocol which stains extracellular matrix components to highlight folli-
cles. Note heterogeneous distributions of follicles (white arrowheads), with 
hardly any follicles present in À gure a, while clustering of follicles can be ob-
served in À gure b. Figure c shows a magniÀ ed pre-antral follicle with an oo-
cyte surrounded by a single layer of granulose cells. Original magniÀ cation: 
100 x. Scale bar in À gure a and b represents 250 õm, and in À gure c 50 õm. 
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Contribution of resident oestradiol content of ovarian cortical biopsy to 
total oestradiol release
Figure 4: Distinction between resident and de novo synthesized oestra-
diol. Oestradiol levels were determined in conditioned medium from fresh 
tissue, tissue with maximal cryodamage (MCD), and in tissue lysates. Lysates 
were prepared using two different protocols; dismembrator method and 
mortar method. Ovaries were derived from separate animals. Levels of 
oestradiol present in culture medium are shown for comparison.
Our results with MCD-samples shown in À gures 1 and 2, strongly suggest pro-
duction de novo rather than release by diffusion of oestradiol already present 
in the ovarian biopsies. We decided to assess the possible contribution of 
resident oestradiol to the observed total oestradiol release levels in more de-
tail. To this end, we prepared lysates of fresh (noncultured) ovarian cortical 
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biopsies via two different protocols (mortar or dismembrator), and measured 
their oestradiol content. As shown in À gure 4, the oestradiol present in the 
two types of lysates generally did not exceed oestradiol levels released by the 
MCD-samples, indicating that oestradiol released by vital biopsies is indeed 
constituted almost entirely by de novo production, subsequent diffusion, and 
release into the medium during the culture period.
Oestradiol release by biopsies derived from cryopreserved intact bovine 
ovaries
To assess the relevance of our assay for the assessment of follicular survival 
after the cryopreservation of an intact ovary, we perfused two ovaries (in-
dependent experiments) with a standard 10% ME²SO solution, followed by 
cryopreservation, storage in liquid nitrogen, and subsequent thawing. From 
these ovaries cortical biopsies were taken, cultured for 7 days, and oestradi-
ol levels were determined. For reference values, cortical biopsies from the 
same ovaries were subjected to the maximal cryo-damage inducing procedure 
and cultured as well. As shown in À gure 5, results obtained from the 2 ova-
ries were very similar. In both instances, we were able to detect oestradiol 
levels that were 2-3 times higher in vital biopsies compared to MCD biopsies, 
indicating that viable 17ß-oestradiol-producing follicles were still present in 
the cryopreserved tissue. Compared to the mean oestradiol level released 
by fresh biopsies from 8 separate ovaries presented in À gure 2b, oestradiol 
release by biopsies from the two cryopreserved ovaries had dropped by ap-
proximately 70%, indicating that the standard method of cryopreservation as 
presented in literature may not yield optimal functional follicular survival. 
Oestradiol release in the day 5-7 period in the two cryopreserved ovaries was 
decreased with 56 and 61% respectively, compared to the 0-4 day period. This 
decrease is in the same range as the mean decrease observed for fresh ovaries 
(45%, À gure 2b).
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Figure 5: Oestradiol release by cultured cortical ovarian biopsies from two 
ME²SO perfused and liquid nitrogen preserved intact bovine ovaries, derived 
from two animals. Oestradiol release by biopsies with MCD is shown for com-
parison.
Discussion 
Of the several options to preserve fertility of women undergoing fertili-
ty-threatening therapies, cryopreservation of an intact ovary may in a num-
ber of instances have additional value compared to the currently existing 
options. Considering the difÀ culties that will be encountered while freezing 
intact organs such as ovaries, it is clear that selection of the optimal cryo-
preservation procedure is a prerequisite before this option can be offered to 
human subjects. This procedure should be aimed speciÀ cally at preserving 
primordial and primary follicles, as these constitute the follicular reserve 
after retransplantation of the intact ovary.
As oestradiol is only produced by theca-containing follicles (more speciÀ cal-
ly, secondary and antral follicles), the outcome of our assay is in theory an 
indication for the number of secondary and antral follicles that is present in 
the biopsies. We are fully aware of the fact that, as a consequence, our assay 
does not directly measure the survival of the target population of primordial 
and primary follicles. Theoretically, the optimal cryopreservation conditions 
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may differ for primordial and primary, versus secondary and antral follicles. 
This may be due to the fact that cells in different stages of development show 
different susceptibility to cryodamaging events, and/or react differently to 
the protective effects of cryoprotectants (Fuller and Paynter, 2004;Siebzehn-
rubl, Kohl et al., 2000). Data from literature, indeed suggest that secondary 
and antral follicles do not tolerate freezing and thawing as well as primordial 
and primary follicles (Gosden, 2002). As our assay monitors the most vulner-
able subpopulation of follicles, it may therefore be considered as a sensitive 
assay for the survival of total follicle population. 
We have shown that bovine cortical ovarian biopsies produce and release con-
siderable amounts of oestradiol in the culture medium. The oestradiol release 
was highest during the À rst 4 days of culture, but also in the 3 consecutive 
days considerable oestradiol levels could be measured, indicating follicular 
survival beyond the 4 day period. The observed decrease in oestradiol release 
after 4 days can most probably be attributed to tissue degeneration in the 
course of time, as, obviously, our culture system is not designed to sustain 
the survival of large tissue fragments for prolonged (> 1 week) periods of 
time. It should be noted that our assay provides information on cryo-damage 
and follicular survival for up to one week after completion of the cryopreser-
vation procedure, whereas the currently used cellular assays (apoptosis de-
tection etc.) only provide information on cryo-damage that is present at one 
time point shortly after the procedure. At this time point, the effects of the 
cryo-damage may not yet have become apparent.
An important consideration for the usefulness of our assay is the origin of the 
oestradiol we measured in the culture supernatants. In vitro oestradiol re-
lease in medium from cultured ovarian tissue has been shown before (Huang, 
Mo et al., 2008;Isachenko, Isachenko et al., 2008a;Isachenko, Isachenko et 
al., 2007;Isachenko, Lapidus et al., 2009). In general, oestradiol secretion 
by cortical biopsies in vitro could be readily measured up to two weeks of 
culture (Isachenko, Isachenko et al., 2008b; Morimoto, Oku et al., 2007). 
However, differences in the species of which the ovarian tissue originated 
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and differences in the amount of cultured cortical tissue, culture volumes 
and time points of sampling make direct comparison to the results presented 
in this study very difÀ cult. In theory, oestradiol found in culture supernatants 
may represent only resident (meaning already present at the start of the 
culture) oestradiol that slowly diffuses out of the cortical biopsies during 
the culture period, rather than oestradiol produced de novo. In this study, 
we actually provide evidence that the observed estradiol levels represent 
for the larger part estradiol that is produced de novo. More speciÀ cally, the 
contribution of resident oestradiol to our measurements was approximately 
15% of the amount produced by fresh biopsies, indicating that 85% was newly 
synthesized oestradiol. The fact that some oestradiol was already present in 
the cortical biopsies before start of the culture, strongly suggests that oestra-
diol production is not an artifact induced by the in vitro culture process, but 
rather is a naturally occurring phenomenon.
We observed a considerable intra- and inter-ovary variation in oestradiol pro-
duction. Several factors may contribute to this variation. One obvious ex-
planation for the observed intra-follicular variation would be a non-random 
distribution of follicles within the ovarian cortex, resulting in different num-
bers of follicles (and consequently different levels of oestradiol production) 
in each cortical biopsy. This was conÀ rmed by performing an extracellular 
matrix staining that highlighted follicular structures, demonstrating a highly 
clustered follicular distribution that was also observed in human ovaries (Gos-
den, 2002; Oktay, Nugent et al., 1997; Schmidt, Byskov et al., 2003).
The inter-ovary variation in oestradiol production may be affected by age of 
the donor, and/or the phase of the cycle at the moment of ovary removal. 
We have not been able to link the age of the donor to oestradiol production 
levels. Evidence for an inÁ uence of the phase of the cycle was provided by 
our À nding that biopsies derived from ovaries in the luteal phase produced 
signiÀ cantly higher levels of 17ß-oestradiol than biopsies derived from ovaries 
in the follicular phase. Further studies to elucidate this matter are obviously 
required.
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To further assess the usefulness of our assay to evaluate different cryopres-
ervation protocols, we performed preliminary experiments in which we per-
fused intact ovaries with the ME²SO containing cryopreservation solution em-
ployed by Martinez Madrid et al 2004 (Martinez-Madrid, Dolmans et al., 2004). 
After freezing of the ovary, storage in liquid nitrogen for one week, thawing 
and reperfusion to remove the ME²SO, cortical biopsies were cultured and 
oestradiol was determined in the culture supernatants. Oestradiol production 
could be readily measured in these supernatants. Compared to the mean oes-
tradiol production by biopsies derived from eight fresh ovaries, the oestradiol 
production had decreased by about 70%, indicating considerable cryo-dam-
age induced by this particular cryopreservation protocol. Our results thereby 
clearly demonstrate the necessity for further optimization of the cryopreser-
vation procedure. Furthermore, we show that our assay may provide a valu-
able addition to the current array of tests and techniques that are available 
for the assessment of damage induced in cryopreserved ovarian tissue.
The observed variation of oestradiol production levels implies that several 
ovaries will have to be tested for each different protocol. In future studies 
we will attempt to reduce this variation by taking the phase of the cycle of 
the donor into account. In addition, other soluble factors that are produced 
by subsets of follicles will be assessed for their capacity to act as an indicator 
of follicular survival after cryopreservation. Other interesting candidates may 
be locally produced factors such as anti-Müllerian hormone and growth dif-
ferentiation factor 9, that play an important role in follicular development.
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Abstract
For some patients, the autotransplantation of a cryopreserved–thawed intact 
ovary might be the best option to preserve their reproductive potential after 
fertility-threatening treatment. The best procedure to successfully cryopre-
serve a human ovary without inÁ icting a devastating level of cryodamage is 
to date unknown. To optimize this procedure, this study developed an assay 
to monitor the extent of cryodamage inÁ icted on bovine ovarian tissue by 
different cryopreservation protocols. The assay measures glucose and lactate 
metabolism of ovarian tissue fragments in vitro and determines the extent of 
cryodamage in cryopreserved ovaries. This study tested the cryoprotective 
effect of two different routes of administration of the cryoprotectant di-
methylsulphoxide (DMSO). The cryoprotective effect was assessed in different 
tissue layers of the ovary, namely the cortex, the subcortex and the medulla. 
Submersion of intact ovaries in DMSO prior to freezing–thawing resulted in the 
complete protection of the glucose/lactate metabolism of the cortex, but 
not of the inner ovarian mass. Perfusion without simultaneous submersion, 
resulted in partial protection of cortex, subcortex and medulla, while the 
combination of submersion and perfusion conveyed the highest level of pro-
tection for all three ovarian tissue layers. 
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Introduction
With prospects of survival improving, fertility preservation is becoming in-
creasingly relevant for cancer patients that undergo fertility threatening 
treatments, such as chemo- or radiotherapy. Several options to preserve 
fertility can nowadays be offered (Donnez et al. 2006; Sonmezer and Ok-
tay, 2004; Wallace et al., 2005; Demeestere et al., 2009; Diedrich et al., 
2011), including the cryopreservation and autotransplantation of ovarian cor-
tex strips. This approach has already resulted in the birth of a number of 
healthy offspring (Donnez et al., 2004; Meirov et al., 2005; Demeestere et 
al., 2007; Silber et al., 2008b and others). Cryopreservation of cortical strips 
has already become a clinically relevant treatment modality. For a selected 
group of patients, the cryopreservation of an intact ovary may be an as yet 
experimental but promising option. (Kim et al., 2010; Diedrich et al., 2011; 
Bromer and Patrizio, 2009). Transplantation of a fresh intact human ovary is 
in fact technically possible. Silber et al. (2008a) have performed this proce-
dure between identical twin sisters, resulting in healthy offspring. While the 
optimal procedure for the cryopreservation of cortical strips has been eluci-
dated (Gook et al., 2000; Kagawa et al., 2009; Newton et al., 1998), cryo-
preservation of an intact organ is technically more challenging. The structural 
components of an ovary, its vascular system, the oocytes and the primordial 
follicles within the ovary, are all crucial for maintaining a functional organ 
after cryopreservation and thawing. All these different ovarian components 
may require different cryoprotective protocols, considering the different cell 
types that constitute them. 
To address this problem, this study elaborated on previous work present-
ing the cryopreservation of intact ovine ovaries, using dimethylsulphoxide 
(DMSO) as a cryoprotectant (Arav et al., 2010; Bedaiwy et al., 2003; Imhof et 
al., 2006; Revel et al., 2004). In addition, both Bedaiwy et al. (2006) and Mar-
tinez-Madrid et al. (2004, 2007), have made a À rst attempt at cryopreserving 
human ovaries, by perfusing them with a 10% DMSO solution. In these studies, 
cryodamage in the ovarian tissue was assessed by viability tests, electron 
microscopy and analysis of cells undergoing apoptosis.
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This study developed a new assay to measure the degree of cryodamage that 
the ovarian tissue has sustained that is based on glucose and lactate me-
tabolism. For obvious ethical and practical reasons, human ovaries are not 
suitable and/or available for the elaborate testing of a large number of differ-
ent cryoprotective regimes. Therefore, a previously described bovine model 
system was used (Gerritse et al., 2008, 2010). Bovine ovaries are similar to 
human ovaries with respect to their size, cycle and the number of develop-
ing follicles per cycle. In the current study, the glucose/lactate assay was 
used in this bovine model system to evaluate the sensitivity to cryodamage 
of the stromal cell compartment of the ovary. Until now, hardly any attention 
has been given to this cell type. Stromal cells constitute at least 90% of the 
ovarian tissue mass and are present in all tissue layers of the ovary. They are 
therefore imperative for maintaining organ integrity and functionality after 
freezing–thawing. An additional rationale to focus on stromal cell survival is 
the observation that stromal cells are vital for optimal follicular development 
(McLaughlin and McIver, 2009). Finally, the metabolically active stromal cells 
have been described to be more sensitive to cryodamage than the quiescent 
primordial oocytes (Kim et al., 2004), emphasizing the need for a cryopreser-
vation protocol that not only efÀ ciently preserves the follicles/oocytes, but 
the stromal cell compartment as well.
This study investigated the route of administration of the cryoprotectant, 
namely either submersion of the organ in a DMSO-containing solution or per-
fusion with DMSO via the vascular pedicle.
Materials and methods
Ovary collection
Intact bovine ovaries were collected at a local abattoir essentially as de-
scribed previously (Gerritse et al., 2008, 2010). BrieÁ y, ovaries (n = 6) used 
for culturing of fresh cortical, subcortical and medullar biopsies were collect-
ed on ice and transferred to the laboratory for further preparation. Ovaries (n 
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= 30) used for cryopreservation experiments were perfused on site, with 15 ml 
Ringers’ solution (Baxter, Utrecht, The Netherlands) containing 50 IE/ml hep-
arin (Leopharm, Breda, The Netherlands) and 2.5% methylene blue (Clinical 
Pharmacy, Nijmegen, The Netherlands) via the vena ovarica. Time between 
death of the animal and start of the perfusion was kept to a minimum (20–40 
min). The efÀ ciency of the perfusion was monitored by the appearance of 
blue colouration at the ovarian surface. After the perfusion, the ovaries were 
transported on ice to the laboratory.
Cryopreservation and thawing of intact ovaries
Intact ovaries were cryopreserved basically as described by Martinez-Madrid 
et al. (2004, 2007) with some modiÀ cations. For submersion experiments, the 
ovaries (n = 13) were placed in a bath containing 30 ml Dulbecco’s modiÀ ed 
Eagle medium (DMEM; PAA laboratories, Pasching, Austria) and 2% fetal calf 
serum (FCS; Gibco, Breda, The Netherlands) in the presence or absence of 
10% DMSO (Sigma–Aldrich, Zwijndrecht, The Netherlands) for 15–180 min. For 
perfusion experiments (n = 17), a blunt-ended needle (23g Olive Tipped Can-
nula Curved; Aspen Medical, USA) was inserted in to the arteria ovarica and 
secured using a small clamp (Gerritse et al., 2008). All vessels other than the 
vena ovarica and the arteria ovarica, were occluded using clamps.Perfusion 
was performed for 5 or 30 min with a solution of DMEM supplemented with 
2% FCS, 2.5% methylene blue and 10% DMSO for 5 min to 120 min using a 
peristaltic STC-521 syringe pump (Terufusion, Tokyo, Japan) at a Á ow rate of 
2.5 ml/min. During perfusion backÁ ow of the (blue) perfusion Á uid from the 
vein was observed. No leakage of perfusion Á uid from the clamped vessels 
was observed, illustrating the efÀ ciency of the procedure. After the perfu-
sion, the ovaries, with the blunt-ended needle still inserted, were transferred 
to a sterile 100-ml semen collection container (Deltalab, Barcelona, Spain) 
containing DMEM and 2% FCS with or without 10% DMSO, which was subse-
quently placed into a 5100 Cryo Freezing Container (Nalgene, VWR, Belgium; 
precooled to 4°C) and left on ice for 15 min. Subsequently the container was 
transferred to a 80°C freezer overnight to allow for a gradual decrease in 
temperature, followed by submersion in liquid nitrogen for at least 1 week.
Chapter 5
98
Ovaries were thawed at 60°C for 10 min followed by an incubation at 37°C 
for 20 min. After thawing the ovary was taken from the container, submerged 
in 30 ml DMEM and 2% FCS, and reconnected to the peristaltic pump. The 
cryoprotectant was gradually removed by three additional perfusion steps of 
10 min each at room temperature with a Á ow rate of 2.5 ml/min using DMEM 
and 2% FCS with 0.25 mol/l sucrose, DMEM and 2% FCS with 0.1 mol/l sucrose, 
DMEM and 2% FCS without sucrose. After perfusion, ovarian biopsies were 
prepared and cultured as described below.
Preparation and culturing of ovarian biopsies
From either fresh or cryopreserved–thawed ovaries, end-to-end tissue rods 
were prepared. In these tissue rods, the boundary between the cortex and 
medullar tissue could be observed macroscopically. First, the two cortex frag-
ments on either end of the tissue rods were removed. The remaining tissue 
was subsequently divided into four pieces of equal length of approximately 
2–3 mm. The two outer pieces and the two inner pieces were designated sub-
cortex and medulla, respectively (Figure 1).
Figure 1: Preparation of ovarian fragments from different tissue layers. 
Tissue rods (shown at the bottom) were obtained by taking end-to-end punch 
biopsies from the ovary, with a diameter of 6 mm. Next, tissue rods were 
divided into two cortical, two subcortical and two medullar fragments of 
comparable length (2 - 3 mm).
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Biopsies were transferred to six-well plates (Falcon, Heidelberg, Germany) 
for culturing. For each ovary, duplicate wells were prepared. Each well con-
tained either three cortical, three subcortical or three medullar biopsies in 5 
ml DMEM culture medium supplemented with 10% FCS and 40 õg/ml gentam-
ycin. At day 4 of culture, spent medium was collected and 5 ml fresh medium 
was added to the wells, followed by an additional culture period of 3 days. 
Glucose and lactate content of culture supernatants were determined using 
a standard blood-gas analyser (Chiron Diagnostics, Bayer, Germany). At the 
end of the culture period, biopsies were weighed and glucose and lactate 
production and consumption were normalized (and expressed) per milligram 
of tissue per day.
Monitoring the temperature during cryopreservation
Figure 2: (a) Scematic representation of the different temperature monitor-
ing points of an ovary frozen in a passive cooling device. (b) Temperature 
kinetics at the monitoring points indicated in (a), shown at 4-min intervals. 
DMSO= dimethylsulphoxide.
The cryokinetics within an intact ovary in the absence of any cryoprotective 
measures and in the surrounding Á uids during the freezing process were mon-
itored every 3.5 s using a set of microthermometers (Labfacility Temperature 
Technology, West Sussex, UK) with an accuracy of 0.1°C. Temperature was 
monitored in the ovarian cortex and medulla, in the container containing the 
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ovary and the DMSO solution, in the passive cooling device and in the freezer. 
The microthermometers measuring the temperature in the ovary were insert-
ed in the core and just under the surface of the organ, to measure medullar 
and cortical temperature, respectively (Figure 2). 
Histochemical staining
Sections of ovaries were À xed overnight in phosphate-buffered 4% formalde-
hyde and embedded in parafÀ n. Sections (5 õm) were stained with haematox-
ylin and eosin. Tissue sections were analysed by conventional light microscopy 
(x100) and photographed. 
Statistical analysis 
Data were tested for normality using GraphPad Prism version 4.00 for Win-
dows (GraphPad Software, San Diego, California, USA; www.graphpad.com) 
and found to be normal. Two-sided Student’s t-test was performed using the 
same software package. 
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Results 
Cryoprotective effect of submerging intact ovaries in DMSO on the glucose/
lactate metabolism of different tissue layers. To investigate the cryoprotec-
tive effect of DMSO, intact ovaries were submerged in a 10% DMSO solution, 
frozen, stored in liquid nitrogen and than thawed. Subsequently, tissue bi-
opsies were taken from the cortex, the subcortex and the medulla. Biopsies 
were cultured for 1 week. Glucose and lactate concentrations were deter-
mined in the spent culture media after 4 days of culture (days 1–4) and again 
after another 3 days of culture (days 5–7) (Figure 3). The glucose/lactate 
metabolism of fresh (i.e. non-frozen, non-thawed) tissue (Figure 3, condition 
A) was used as reference value. Glucose consumption in the cortex (Figure 3, 
left panels) increased signiÀ cantly (P < 0.0001) during the second culture pe-
riod (days 5–7), whereas lactate production did not change during the entire 
culture period. As shown in Figure 3 (middle and right panels), the same holds 
true for the fresh subcortex and the medullar tissue (P = 0.001 and 0.0003, 
respectively).
When freezing intact ovaries without any cryoprotective measures (Figure 3, 
condition B), the glucose/lactate metabolism of the cultured tissue fragments 
decreased, compared with fresh tissue, by more than 80% during days 1–4 
and by more than 90% during days 5–7. To assess the cryoprotective effects of 
DMSO on ovarian tissue, intact ovaries were submerged in a 10% DMSO solution 
for different lengths of time (ranging from 15 to180 min) prior to freezing–
thawing and subsequent tissue culture. Submerging the ovary in DMSO for 15 
min (Figure 3, condition C), resulted for the cortex in a complete protection 
of glucose/lactate metabolism. Glucose consumption in days 5–7 showed a 
small albeit signiÀ cant (P < 0.05) decrease, compared with fresh tissue. Lev-
els of glucose/lactate metabolism of the subcortex and the medulla, on the 
other hand, were not protected at all by the 15-min DMSO submersion. In 
these tissue layers, glucose consumption as well as lactate production were 
at levels comparable to those of unprotected ovaries. Increasing the submer-
sion time of the ovaries in DMSO prior to freezing from 15 min to 30, 60, 120 
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(data not shown) or even 180 min (Figure 3, 235 condition D) did not increase 
protection against cryodamage of the subcortex and the medulla. 
The speed of temperature change in the different tissue layers during the 
freezing procedure was investigated, as variations in this may have contrib-
uted to the lack of protection from cryodamage by DMSO in the medulla com-
pared with the cortex. Temperature was monitored at À ve different locations 
(Figure 2a) during the freezing process. As expected, temperature outside the 
cooling device dropped quickly, reaching 70°C after about 5 min (Figure 2b). 
The temperature in the cooling device and in the container declined more 
slowly. Temperature in the two locations within the ovary dropped at an even 
slower pace. No signiÀ cant difference in temperature was observed between 
the ovarian cortex and the medulla.
Glucose/lactate metabolism of cryopreserved intact bovine
 ovaries as a novel quantitative marker to assess tissue cryodamage
103
Figure 3: Glucose uptake (a) and lactate production (b) of cultured ovar-
ian fragments derived from cortex, subcortex and medulla. Glucose/lac-
tate metabolisme was determined at two different time points of culture; 
days 1-4 and days 5-7. Condition A: fresh (non-cryopreserved) tissue; con-
dition B: tissue frozen-thawed without cryoprotective measures; condition 
C: tissue frozen-thawed after submersion in DMSO for 15 min; condition D: 
tissue frozen-thawed after submersion in DMSO for 180 min. Values are mean 
and SD. Numbers above bars represent the number of ovries analysed per 
condition. + = treatment applied; - = treatment not applied; NA = not appli-
cable.
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Figure 4: Glucose uptake (a) and lactate production (b) of cultured ovar-
ian fragments derived from cortex, subcortex and medulla. Glucose/lac-
tate metabolism was determined at two different time points of culture; 
days 1-4 and days 5-7. Condition A: fresh (non-cryopreserved) tissue; con-
dition E: tissue frozen-thawed after 30 min perfusion, without submersion; 
condition F: tissue frozen-thawed after submersion in, and perfusion with, 
DMSO for 5 min; condition G: tissue frozen-thawed after submersion in and 
perfusion with DMSO for 30 min. Values are mean and SD. Numbers above 
bars represent the number of ovaries analysed per condition. + = treatment 
applied; - = treatment not applied; NA = not applicable.
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Effect of perfusing intact ovaries with DMSO on glucose/lactate metabolism
Intact ovaries were perfused with a 10% DMSO solution containing methylene 
blue prior to freezing and were submerged in medium with or without DMSO 
during the perfusion. During a successful perfusion, this study observed mac-
roscopically that the surface of the ovary actually turned blue rapidly (within 
seconds after start of the perfusion), whereas during failed perfusions no 
colour change was observed. The latter ovaries were not used for glucose/lac-
tate metabolism analysis. Results are shown in Figure 4 (conditions E, F and 
G). As for Figure 3, the metabolism of fresh tissue is shown for comparison 
(condition A). For clarity, data are summarized in Table 1.
Table 1: Summary of effects of different cryoprotective treatments on ovar-
ian tissue metabolisme.
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In contrast to the complete protection of the cortex by submerging the ovary 
in DMSO, perfusing the ovary for 30 min (i.e. without submersion) did not 
result in a complete protection of the cortical layer. Instead, only 30–50% of 
the metabolic activity of fresh tissue remained (Figure 4, left panels, con-
dition A versus E). The subcortical and medullar tissue layers, on the other 
hand, clearly beneÀ tted from the perfusion treatment (Figure 4, middle and 
right panels, condition A versus E): in contrast to the submersion experiments 
where hardly any metabolic activity remained (Figure 3), 30–70% of the fresh 
values were now found. 
As both perfusing with DMSO (for the subcortex and medulla), as well as sub-
merging in DMSO (for the cortex), displayed protective effects, the treat-
ments were combined. The effects of 5-min (Martinez-Madrid et al., 2004, 
2007) or 30-min perfusion, in combination with submersion were analysed 
(Figure 4, conditions F and G). After combining perfusion and submersion for 
5 min, the cortex (left panels) was protected to a level of metabolic activity 
approaching that of fresh tissue (condition A versus F). It should be noted, 
however, that a similar level of protection was already achieved by submer-
sion in a DMSO solution alone (Figure 3, condition C and D). The same treat-
ment resulted for the subcortex (Figure 4, middle panels, condition A versus 
F) and medulla (left panels) in a level of glucose/lactate metabolism that 
was not maximal (reaching 25–50% of the fresh values), but clearly increased 
compared with the level of metabolism obtained by submersion only. 
Increasing the combined submersion and perfusion time from 5 to 30 min led 
to higher glucose/lactate metabolism in both subcortex and medulla, but 
these levels were still suboptimal (50–70% of the fresh values). Increasing the 
perfusion time to 60 min, and even 120 min, did not result in an additional 
protective effect on the ovarian tissue (data not shown).
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Figure 5: Haematoxylin-eosin-stained ovarian medullar tissue fragments 
derived from intact ovaries. (A) Tissue derived from unfrozen non-cultured 
ovary. (B-D) Fragments were cultured for 7 days. (B) Tissue derived from 
fresh (unfrozen) ovary; (C) tissue derived from a frozen-thawed ovary in 
the absence of DMSO; (D) tissue derived from a frozen-thawed ovary in the 
presence of DMSO. Some pycnotic cells are indicated by arrowheads. Bar = 
100 õm.
Histology reÁ ects the metabolic status of cultured ovarian tissue fragments
It is to be expected that cryodamage inÁ icted on ovarian tissue is not only 
reÁ ected by the level of metabolic activity of this tissue, but also by its histo-
logical appearance. To test this notion, this study performed standard haema-
toxylin and eosin staining of cultured ovarian tissue derived from the medulla 
of intact ovaries that were either fresh (non-frozen) or cryopreserved in the 
presence or absence of DMSO. Unfrozen, non-cultured tissue was also stained 
for reference. This tissue (Figure 5A) showed relatively large, lightly stained 
nuclei and a regular pattern of extracellular matrix À bres. In the cultured 
tissues (Figure 5B–D), the nuclei were smaller and more intensely stained. In 
addition, the extracellular matrix that surrounded the stromal cells appeared 
to be less organized. Culturing unfrozen (fresh) tissue induced the formation 
of a limited number of pycnotic (i.e. small and dark) nuclei, indicative of a 
decrease in tissue viability (Figure 5B), as can be expected after 7 days of 
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culture. Freezing and thawing the intact ovary before tissue culture clearly 
increased the number of pycnotic cells, irrespective of the absence (Figure 
5C) or presence (Figure 5D) of DMSO. The apparent decrease in tissue viabil-
ity is in accordance with the absence of metabolic activity in these medullar 
tissues, as shown in Figure 4.
Discussion 
Several studies have dealt with determining the optimal conditions for cryo-
preserving intact ovaries, using various techniques to assess cellular damage 
(mainly in follicles/oocytes). Each of these assays has its own advantages and 
limitations. Results obtained by conventional histology (Arav et al., 2005; 
Baudot et al., 2007; Bedaiwy et al., 2003; Courbiere et al., 2005, 2006; Mart-
nez-Madrid et al., 2004) and transmission electron microscopy (Camboni et 
al., 2008; Martinez-Madrid et al., 2007) have in common that they are, in 
contrast to the glucose/lactate assay, difÀ cult to quantify. The current study 
found that the number of pycnotic stromal cells was increased in cryodam-
aged and cultured ovarian tissue. However, quantifying the amount of cryo-
damage by assessing the number of pycnotic cells is time consuming and often 
difÀ cult as the pycnotic status of the nuclei is not always evident.
Apoptosis assays (Bedaiwy et al., 2003, 2006; Martinez-Madrid et al., 2007; 
Xiao et al., 2010) assess programmed cell death at distinct moments in time 
but may underestimate the actual amount of tissue damage that has been 
inÁ icted by the cryopreservation process. The glucose/lactate assay is not 
limited to determining cryodamage at one particular moment after thaw-
ing, but instead measures the accumulated effects of the cryodamage that 
occurs over a 7-day period. Viability assays (Arav et al., 2005; Baudot et al., 
2007; Bedaiwy et al., 2003, 2006; Courbiere et al., 2005, 2006; Imhof et al., 
2004; Martinez-Madrid et al., 2004) are predominantly designed for intact 
(cultured) tissue monolayers rather than tissue sections and are therefore not 
optimally suited for determining cryodamage in tissue.
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In addition to tests that analyse cryodamage based on morphological parame-
ters, several assays measure the production or secretion of speciÀ c cell prod-
ucts such as oestradiol (Gerritse et al., 2010; Isachenko et al., 2007), lactate 
dehydrogenase (LDH; Newton et al., 1998) and cAMP (Wallin et al., 2009). 
However, oestradiol secretion does not take the stromal compartment of the 
ovary into account, while the biological variation in oestradiol secretion is 
too large to obtain signiÀ cant results (Gerritse et al., 2010). LDH is a large in-
tracellular tetrameric protein that will most likely not be efÀ ciently released 
into the culture medium and is therefore not suitable for the purposes of 
this study. cAMP production, À nally, could only be measured after stimulating 
the tissue with the adenylyl cyclase activator forskolin (Wallin et al., 2009), 
whereas glucose/lactate metabolism is a general marker that is also present 
in unstimulated tissue. 
A third category of assays looks at cell proliferation, for instance via bromo-
deoxyuridine uptake (Onions et al., 2008). Cell proliferation, however, is un-
likely to occur in, non-stimulated ovarian tissue, with the possible exception 
of granulosa cells, and is therefore not suitable.
When searching for the optimal condition(s) to cryopreserve an intact ovary, 
the study elaborated on the experimental conditions used in previous stud-
ies. Martinez-Madrid et al. (2004, 2007) used a protocol employing a 5-min 
perfusion with 10% DMSO, in combination with submersion of the ovary in 10% 
DMSO. The authors described that, after this treatment, a 75% survival of 
follicles, viable stromal cells and viable blood vessels were observed in the 
ovarian tissue. Since these data on stromal cell viability were not quantiÀ ed, 
the current study decided to employ a quantitative glucose/lactate assay to 
analyse the cryoprotective effect of DMSO, for three different ovarian tissue 
layers separately. Whereas the distinction between the cortex and medulla 
is both functionally, macroscopically and histologically apparent (Gerritse et 
al., 2010), the separation made between subcortex and medulla is not. The 
current study made this division to detect possible differences between the 
tissue layer immediately beneath the cortex (the subcortex) and the core of 
the organ (medulla).
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The results show that submersion is sufÀ cient for an efÀ cient protection of 
the cortex. Submersion alone, even after increasing the exposure time to 3 
h, did not protect the tissue beyond the cortex. It was found that administra-
tion of DMSO via a 5-min perfusion, as described by 405 Martinez-Madrid et 
al. (2004, 2007), provided some level of protection. Increasing the perfusion 
time to 30 min, however, clearly improved the protection against cryodam-
age, conÀ rming the results obtained by Milenkovic et al. (2011).
The contrast between the complete protection of the cortex and the lack of 
protection of the deeper tissue layers was puzzling. Monitoring the tempera-
ture kinetics during the freezing process showed that a (too) slow decrease in 
the temperature of the deeper tissue layers (resulting in suboptimal freezing 
conditions and consequently in tissue damage) was not the cause of the lack 
of protection, as temperature kinetics in the ovarian cortex and the medul-
la during freezing were practically identical. This suggests that homogenous 
cooling, i.e. according to Arav and Natan (2009), one of the limiting factors 
of successful whole organ freezing, is most probably not a limiting factor in 
the current freezing protocol. Most likely, DMSO is not able to penetrate the 
ovarian tissue beyond the cortical layer, irrespective of the incubation time. 
Analysis of ovarian tissue stained histochemically via the Azan protocol (Ger-
ritse et al., 2010) revealed that the ovarian cortex contains, in contrast to 
the subcortex and the medulla, large amounts of extracellular matrix compo-
nents, whereas the number of stromal cells in the cortex is relatively low. As 
DMSO is likely to progress throughout tissue around rather than through cells, 
this process will proceed more easily in tissue that contains relatively few 
cells and is rich in extracellular matrix. 
Perfusing the ovary with DMSO for 30 min resulted in a partial (about 40–50%) 
protection against cryodamage of the subcortical and medullar tissue layers. 
The cortex, however, was less well protected against cryodamage by perfu-
sion alone compared with submersion (about 30% protection). The fact that 
the cortex is less well vascularized than the subcortex and the medulla (Del-
gado-Rosas et al., 2009), may explain why the DMSO did not reach the cortical 
layer in sufÀ cient amounts to provide optimal protection. 
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The next logical step was to combine submersion and perfusion. A 5-min per-
fusion–submersion period resulted in optimal protection of the cortex and 
some protection of the deeper layers. No additional protective effect was 
obtained by prolonging the perfusion time beyond 30 min. A further increase 
in the protection level may require higher DMSO concentrations, and/or other 
types, or even combinations, of cryoprotectants. In this context, however, it 
should be noted that it is currently unknown what extent of cryodamage is 
acceptable for maintaining organ integrity and functionality after transplan-
tation. It is conceivable that complete protection is not required and that our 
current protocol already provides a sufÀ cient level of protection. This notion 
can only be tested in vivo, for instance by transplanting a cryopreserved ovary 
into an immune-compromised host. Resumption of the physiological function 
of the ovary, including sufÀ cient circulation, and assessment of follicle devel-
opment after stimulation with gonadotrophins can then be analysed. 
As mentioned previously, this study’s assay is aimed at the stromal cell com-
partment. Therefore, it provides no information on the condition of the other 
ovarian compartments, including the follicles, the intraovarian vasculature 
and the vascular pedicle. Damage to the vascular compartment may lead to 
thrombosis and failure to resume function in vivo after reanastomosis (Im-
hof et al., 2006; Onions et al., 2009). To ensure that a functional organ re-
mains after freezing, thawing and transplantation, all ovarian components 
are of equal importance, and require optimal protection levels as well. As 
the aforementioned compartments each consist of many different cell types 
that may each require different cryoprotective measures, a different optimal 
cryoprotective protocol may apply to each compartment. This assay may be 
a valuable tool in delineating and À ne-tuning the deÀ nitive protocol, which 
may be a combination, and perhaps even a compromise, separate of all the 
protocols. Obviously, the vitality of the cell types in other compartments will 
have to be assessed in parallel.
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Abstract
The cryopreservation and subsequent thawing and autotransplantation of an 
intact ovary is as yet an experimental method to preserve the fertility of 
female cancer patients that require fertility reducing anti-cancer therapy. 
Whereas proof of concept of the procedure has been provided in ovine model 
systems, the cryopreservation and thawing of an organ the size of a human 
ovary without inducing a signiÀ cant level of cryodamage, has not yet been 
accomplished.
In this paper we used our previously described bovine model system to devel-
op an optimal cryopreservation and thawing procedure. Bovine ovaries were 
obtained at an abattoir, and were perfused on site with heparin to prevent 
intravascular coagulation. Subsequently, the ovaries were transported to the 
laboratory and subjected to different cryopreservation protocols. As a read 
out system for cryodamage to the stromal compartment of the ovary, we em-
ployed an in vitro metabolic assay. This assay is based on the glucose uptake 
of cultured ovarian tissue fragments. In this model system we investigated 
the cryoprotective effects of several commonly used cryoprotective agents, 
including DMSO, ethylene glycol, butanediol and propanediol. In addition, 
we determined the optimal administration route of the cryoprotectant (per-
fusion and/or submersion), and, À nally, the optimal treatment of the ovary 
prior to the start of the cryopreservation process. After having determined 
the optimal cryopreservation procedure for bovine ovaries, the protocol was 
tested on human ovaries. Conventional histology and immunohistochemistry 
were used to assess the integrity of follicles and vascular endothelial cells, 
respectively.
Of the tested cryoprotectants, only DMSO was able to provide protection 
against cryodamage of cortical, subcortical as well as medullar ovarian tissue. 
A combination of submerging the ovary in a 10% DMSO solution, while simul-
taneously perfusing it with the same solution for 1 hour, provided between 90 
en 100% protection against cryodamage of the ovarian stromal compartment, 
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as assessed with the in vitro glucose uptake assay. For an optimal protection, 
it was crucial to start perfusion of the ovary with the heparin solution as 
soon as possible (within 10-15 minutes) after death of the cow. Ethyleneglycol 
provided some protection of the ovarian cortex, but the deeper tissue layers 
(subcortex and medulla) were not protected, even after prolonged (up to 3 
hours) perfusion. No protection whatsoever was observed with butanediol and 
propanediol. When cryopreserving human ovaries according to the optimized 
protocol, we also observed over 95% protection against cryodamage on all 
tissue levels. In addition, no apparent morphological damage to either the 
follicles or the vascular endothelium was observed.
We have established an optimal protocol for the cryopreservation of an intact 
human ovary that inÁ icts no apparent cryodamage to the stromal compart-
ment of the organ. As morphological assessment of follicular and vascular en-
dothelial cell integrity is not sufÀ cient to assess their viability and functional 
integrity, subsequent research should focus on these issues, to facilitate the 
step towards clinical application of this method of fertility preservation for 
female cancer patients. 
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Introduction 
With treatment modalities improving over the years, the number of cancer 
patients that actually survive their disease is increasing. Parallel to this en-
couraging development, growing attention is being given to the quality of 
life after being cured. However, anti-cancer therapy may reduce fertility or 
even lead to sterility. As being able to start a family is for many people a key 
component of a fulÀ lled life, fertility preservation should be offered prior 
to starting any anti-cancer therapy that might have a negative impact on 
fertility. Nowadays a number of options for fertility preservations is available 
to female patients (Diedrich et al., 2011; Donnez et al., 2006; Sonmezer and 
Oktay, 2004; Wallace et al., 2005). Depending on age, the type and stage of 
the cancer, and the stage of life, the most suitable option will have to be 
selected for each patient individually.
A relatively recent development is the cryopreservation of cortical ovarian 
tissue strips. These tissue strips can, after the patient has been cured of her 
disease, be thawed and autotransplanted, either orthotopically or heteroto-
pically. When the autotransplantation is successful, it results in the (tempo-
rary) resumption of the ovulatory cycle, accompanied by the possibility of 
being able to conceive, either naturally or with the help of IVF. This option 
to preserve fertility is especially suited to prepubertal girls who cannot be 
stimulated hormonally to generate a sufÀ cient number of oocytes for cryo-
preservation, or for adult patients for whom it is not advisable to postpone 
their anti-cancer treatment for the time required to generate either oocytes 
or embryos for cryopreservation. To date, ovarian strip cryopreservation has 
already led to the birth of 23 children worldwide, indicating the viability of 
this option (Donnez et al., 2011a; Donnez et al., 2011b; Donnez et al., 2012; 
Isachenko et al., 2012; Revelli et al., 2013). 
A variation on the cryopreservation of ovarian cortical strips, is the cryopres-
ervation and subsequent autotransplantation of an intact ovary, including its 
vascular pedicle (Bromer and Patrizio, 2008; Imhof et al., 2006; Silber and 
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Gosden, 2007; Silber et al., 2008a; Silber et al., 2008b; Silber, 2012; Arav et 
al., 2010). Whilst having a number of disadvantages (the risk of reintroducing 
the tumour via occult metastatic tumour cells that may be present in the ova-
ry being one of the major concerns), there are also a number of distinct ben-
eÀ ts to this approach. The major one is the prevention of ischemia that occurs 
when ovarian strips are autotransplanted. After surgery, it takes about a week 
for an ovarian tissue strip to become vascularized. During this week many 
follicles in the graft are lost due to ischemia, thereby limiting the time the 
graft can function physiologically. The lifespan of a typical graft is currently 
between several months up to seven years (Donnez et al., 2008; Donnez and 
Dolmans, 2009; Oktay and Karlikaya, 2000; Oktay et al., 2001; Tao and Del, 
2008; Andersen et al., 2012), and after that one or more subsequent auto 
transplantations may be required. When auto transplanting an intact ovary, 
however, ischemic damage is kept to a minimum. As the vascular pedicle of 
the ovary is surgically attached to the circulation, this will result in an imme-
diate resumption of the oxygen and nutrient supply to the graft. In the case 
of pre-pubertal girls who receive an auto transplantation of an intact ovary, 
an additional advantage is that the induction of puberty will be mediated by 
the ovarian graft, preventing the need for an extended period of hormonal 
replacement therapy.
The successful cryopreservation and subsequent thawing of an organ the size 
of an intact human ovary, however, is no small feat. Proof of concept of the 
procedure has been provided by Imhoff and others (Arav et al., 2010; Bedaiwy 
et al., 2003; Imhof et al., 2006; Revel et al., 2004) , who were able to cryo-
preserve and re-transplant an ovine ovary. However, as the size of an ovine 
ovary is much smaller than that of a human ovary (Gerritse et al., 2008), the 
cryopreservation of a human ovary has proven to be technically much more 
complicated. Not only will delivering sufÀ cient amounts of cryoprotectant 
to the entire ovary prove to be more challenging, also the requirements for 
protection against cryodamage may actually differ for the different compart-
ments of the ovary, i.e. the follicles/oocytes, the stromal cell compartment, 
and the vascular system. Technically, the transplantation of a fresh intact 
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human ovary is in fact possible, as shown by Silber et al. (2008), who per-
formed this procedure on identical twin sisters, resulting in healthy offspring. 
Bedaiwy et al. and Martinez-Madrid et al. have both made a À rst attempt at 
cryopreserving human ovaries, by perfusing them with a 10% DMSO solution. 
In these studies, cryodamage in the ovarian tissue was assessed by viability 
tests, electron microscopy and analysis of cells undergoing apoptosis (Bedai-
wy et al., 2006; Martinez-Madrid et al., 2004; Martinez-Madrid et al., 2007).
For ethical and practical reasons it is not possible to use human ovaries for 
developing an optimal cryopreservation procedure. We therefore resorted to 
a bovine animal model, as bovine ovaries are in several aspects (size, dura-
tion of ovulatory cycle, and number of follicles that mature during one cycle) 
comparable to human ovaries (Gerritse et al.,2008) and are readily available 
via the local abattoir. A key factor when trying to establish the optimal cryo-
preservation protocol, is having an adequate read out system to determine 
the level of cryodamage that a given treatment actually can prevent. The 
application of techniques that were previously used to test large numbers 
of different cryopreservation protocols, such as electron microscopy, are ei-
ther too time consuming, or not robust enough. We therefore developed a 
quantitative assay based on glucose/lactate metabolism of cultured ovarian 
tissue (Gerritse et al., 2011) to establish the pre- and post-cryopreservation 
viability of the ovarian tissue. Using bovine ovaries, we have shown that by 
simultaneously submerging an intact ovary in, and perfusing it with, a solution 
containing 10% DMSO, the ovarian cortex is fully protected against cryodam-
age. The deeper ovarian tissue layers (subcortes and medulla), however, were 
only partially protected by this treatment. 
In this paper we describe our efforts to further optimize the cryopreserva-
tion protocol, ultimately leading to a procedure that fully protects the entire 
intact ovary against cryodamage. We then applied this protocol to a limited 
number of human ovaries, also resulting in a complete protection against 
cryodamage, thereby bringing the clinical application of this type of fertility 
preservation a step closer to reality.
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Materials and Methods
Collection of bovine ovaries 
Intact bovine ovaries were collected at a local abattoir essentially as de-
scribed previously (Gerritse et al., 2008; Gerritse et al., 2010) BrieÁ y, ovaries 
(n=68) used for culturing of fresh cortical, sub cortical and medullar biopsies 
were collected on ice, and transferred to the laboratory for further prepa-
ration. Ovaries (n=42) used for cryopreservation experiments were perfused 
on site, with 15 ml of Ringers’ solution (Baxter, Utrecht, The Netherlands) 
containing 50 IE/ml heparin (Leopharm, Breda, The Netherlands) and 2.5% 
methylene blue (Clinical Pharmacy, Nijmegen, The Netherlands) via the vena 
ovarica. Time between death of the animal and start of the perfusion was 
kept to a minimum, but was greatly dependent on the workÁ ow in the abatoir 
(30-40 minutes). In a separate incident we were able to obtain the bovine 
ovaries within 10-15 minutes after the death of the cow, thus enabling a 
much quicker onsite perfusion with heparin. The efÀ ciency of the perfusion 
was monitored by the appearance of blue coloration at the ovarian surface. 
After the perfusion the ovaries were transported on ice to the laboratory for 
further processing.
Human ovaries
Human ovaries were, after informed consent, obtained from 3 different pa-
tients (two BRCA1 patients and one patient with breast cancer; aged 45, 
41 and 35 years, respectively) from the Streekziekenhuis Koningin Beatrix, 
Winterswijk (NL). Approval for the procedure was obtained from the local 
medical ethics committee, provided that the procedure would not interfere 
with the required diagnostic histology. The ovary of each patient, that was 
going to be used to prepare fresh tissue fragments, was stored on ice prior to 
transportation to the laboratory. Of the contra-lateral ovary (which was to be 
cryopreserved), the vascular pedicle was prepared and an 18 GA 1.77, 1.3x 35 
mm canule (VenÁ on) was inserted in the arteria ovarica. These ovaries were 
perfused for 5 minutes with an heparin/methylene blue solution as described 
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for the bovine ovaries. The perfusion was performed within a few minutes 
after the extirpation of the ovary. After perfusion, ovaries were stored on ice 
and transported to the laboratory. 
Cryopreservation and thawing of intact ovaries 
Intact ovaries were cryopreserved basically as described previously (Gerritse 
et al., 2011). For submersion experiments the ovaries (n=26) were placed 
in a bath containing 30 ml of Dulbecco’s ModiÀ ed Eagle Medium (DMEM;PAA 
laboratories, Pasching, Austria) /2 % Fetal Calf Serum (FCS; Gibco, Breda, the 
Netherlands) in the presence or absence (n=5) of 10% cryoprotective agent, 
including dimethylsufoxide (DMSO; Sigma-Aldrich, Zwijndrecht, the Neth-
erlands)(n=5), propanediol (n=4), ethyleneglycol (n=4) or butanediol (n=2) 
for 15-180 minutes. Subsequently, the ovaries were transferred to a sterile 
100 ml semen collection container (Deltalab, Barcelona, Spain) containing 
DMEM/2% FCS with or without 10% of the cryoprotectants mentioned above. 
The container was then placed into a propanol containing 5100 Cryo Freezing 
Container (Nalgene, VWR, Belgium; precooled to 4ÝC), and left on ice for 15 
min. Subsequently the container was transferred to a -80 ÝC freezer overnight 
to allow for a gradual decrease in temperature (detailed in Gerritse et al., 
2011). The container with the ovary was then submerged in liquid nitrogen, 
and stored for at least 1 week. 
For perfusion experiments of ovaries (n=42), a blunt-ended needle (23g Olive 
Tipped Cannula Curved, Aspen Medical, USA) was inserted in to the arteria 
ovarica, and secured using a small clamp (Gerritse et al., 2008). All vessels 
other than the vena ovarica and the arteria ovarica, were occluded using 
clamps. Perfusion was performed for 15-120 minutes min with a solution of 
DMEM supplemented with 2% FCS, 2.5% methylene blue and 10% DMSO or 
ethyleneglycol, using a peristaltic STC-521 syringe pump (Terufusion, Tokyo, 
Japan) at a Á ow rate of 2.5 ml/min. During perfusion, the ovaries were sub-
merged in the same solution as the perfusion Á uid, only without the methyl-
ene blue. During perfusion we observed backÁ ow of the (blue) perfusion Á uid 
from the vein. No leakage of perfusion Á uid from the clamped vessels was 
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observed, illustrating the efÀ ciency of the procedure. After the perfusion, 
the ovaries, with the blunt-ended needle still inserted, were transferred to 
a sterile 100 ml semen collection container (Deltalab, Barcelona, Spain) con-
taining DMEM/2% FCS with or without 10% of the cryoprotectants mentioned 
above, and frozen as described above for the submersion experiments.
Ovaries were thawed at 60ÝC for 10 min followed by an incubation at 37ÝC 
for 20 min. After thawing the ovary was taken from the container, submerged 
in 30 ml of DMEM/2% FCS, and reconnected to the peristaltic pump. The cry-
oprotectant was gradually removed by 3 additional perfusion steps of 10 min 
each at room temperature with a Á ow rate of 2.5 ml/min using DMEM/2%FCS 
with 0.25 M of sucrose, DMEM/2% FCS with 0.1 M of sucrose and DMEM/2%FCS 
without sucrose, respectively. After perfusion ovarian biopsies were prepared 
and cultured as described below.
Preparation and culturing of ovarian biopsies to assess glucose/lactate 
metabolism 
Uptake of glucose and production of lactate by cultured ovarian tissue frag-
ments was performed essentially as described previously (Gerritse et al., 
2011). BrieÁ y from either fresh or cryopreserved/thawed ovaries, end to end 
tissue rods were prepared with a 6 mm diameter biopsy punch (Kai Medical, 
Solingen, Germany) and divided in two cortex fragments, two subcortex frag-
ments and two medulla fragments, each 2-3 mm long. Biopsies were trans-
ferred to 6-well plates (Falcon, Heidelberg, Germany) for culturing. For each 
ovary duplicate wells were prepared. Each well contained either 3 cortical, 
3 sub cortical or 3 medullar biopsies in 5 ml of DMEM culture medium supple-
mented with 10 % FCS and 40 õg/ml gentamycin. At day 4 of culture spent 
medium was collected, and 5 ml of fresh medium was added to the wells, fol-
lowed by an additional culture period of 3 days. Glucose and lactate content 
of culture supernatants was determined using a standard blood gas analyzer 
(Chiron Diagnostics, Bayer, Germany). At the end of the culture period, biop-
sies were weighed, and glucose and lactate production/consumption levels 
were normalized (and expressed) per milligram tissue per day.
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Immunohistochemical staining 
To highlight blood vessel endothelial cells tissue sections of both fresh and 
cryopreserved/thawed human ovaries were À xed overnight in phosphate 
buffered 4% formaldehyde, and embedded in parafÀ n. Five õm sections 
were stained with anti-human Factor VIII as described previously (Gerritse 
et al.,2008) and analysed by conventional light microscopy (x100) and pho-
tographed.
Statistical analysis 
Data were tested for normality using GraphPad Prism version 5.13 for Win-
dows, (GraphPad Software, San Diego, California, USA, www.graphpad.com) 
and found to be normal. Two-sided Student’s t-test was performed using the 
same software package.
Results
Glucose uptake and lactate production in cultured bovine and human ovar-
ian tissue
Our previously described assay to assess the in vitro metabolism of cultured 
bovine and human ovarian tissue fragments involves measuring the uptake of 
glucose as well as the production of lactate. In our experiments, glucose up-
take and lactate production always appeared to be closely linked. We there-
fore decided to conÀ ne ourselves in subsequent experiments to determining 
glucose uptake as a sufÀ cient measure for in vitro metabolic activity of ovar-
ian tissue. 
Protective effect against cryodamage of different cryoprotective agents 
In previous work we have shown that submerging an intact bovine ovary in 
a 10% DMSO solution for 15 minutes fully protects the cortical layer of an 
ovary, but not the deeper (subcortical and medullar) tissue layers. We tried 
to extend the level of protection against cryodamage by testing three other 
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cryoprotective agents that have previously been applied in analogous studies 
(Amorim et al., 2009; Newton et al., 1998) and comparing them with DMSO. 
As shown in À gure 1, the freezing of a bovine ovary (without any protective 
measures) diminished its metabolic activity, after thawing, in the À rst 4 days 
of culture, by more than 80% on all tissue levels (condition 1 versus 2). As was 
to be expected from our previous work, submerging the ovary for 15 minutes 
in DMSO prior to cryopreservation completely protected the ovarian cortex, 
but no effect was found on the subcortical and the medullar level. Substitut-
ing DMSO with either propanediol (condition 4) or butanediol (condition 6) did 
not provide protection on either tissue level against cryodamage, including 
the cortex. Using ethyleneglycol (condition 5), resulted in a varying level of 
protection for the cortical tissue. In 4 different ovaries, a protection level of 
between 19 to 93% (mean: 59%) was found, compared to fresh tissue or tissue 
protected by DMSO. On the deeper tissue layers no protective effect could 
be established. Unexpectedly, the levels of glucose metabolism of subcortical 
and medullar tissue derived from ovaries treated with ethyleneglycol, pro-
panediol or butanediol was much lower than the metabolism in tissue frozen 
and thawed without any protection against cryodamage.
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Figure 1: In vitro glucose consumption of bovine ovarian tissue 
fragments derived from fresh ovaries. (condition 1; positive control 
Ŭ), ovaries cryopreserved and thawed without any protection (condi-
tion 2; negative control Ⱦ) and from ovaries incubated in a solution 
containing 10% DMSO, propanediol, ethyleneglycol or butanediol for 
15 minutes prior to cryopreservation (condition 3 (Ȼ), 4 (¨), 5 (¹) 
and 6 ( ) respectively). Each symbol represents a single ovary. Tis-
sue fragments were collected from the ovarian cortex (left panel), 
the subcortex (middle panel) and from the medulla (right panel). 
Note complete protection against cryodamage of cortical fragments 
derived from ovaries submerged in DMSO, and limited protection by 
ethyleneglycol. The other cryoprotectants displayed no protection at 
all. In the deeper tissue layers, protection against cryodamage was 
observed with neither of the cryoprotectants.
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Whereas a submersion time of 15 minutes is sufÀ cient for DMSO to obtain 
maximum protection in the cortical tissue, the other cryoprotective agents 
might require a longer incubation time to achieve protection. To test this we 
repeated the experiment (cortical fragments only) with a submersion period 
of three hours. The results were basically identical to the previous experi-
ment, meaning full protection of cortical tissue by DMSO, some protection of 
the cortex by ethyleneglycol, and no protective effect with the other cryo-
protective agents (data not shown) .
Since ethyleneglycol was (apart from DMSO) the only cryoprotectant that 
showed any level of protection against cryodamage, we extended our ex-
periments to make sure we did not miss any protective effect caused by this 
agent. As 15 minutes submersion time may have been too short, and three 
hours to long , we included an additional submersion (60 minutes), and we in-
cluded all three tissue layers. Neither submerging the ovary in ethylene glycol 
for 60 minutes, nor examining the deeper tissue layers as well, changed the 
protection proÀ le of ethyleneglycol. In the cortex, varying levels of protec-
tion were observed after submersion for 15, 60 or 180 minutes, whereas DMSO 
already showed 100% protection after 15 minutes. Also in the deeper tissue 
layers no protection was observed (data not shown). In addition, analyzing 
the medium samples conditioned by the cultured ovarian tissue fragments not 
only in the À rst 4 days, but also in the day 5-7 culture period, did not reveal 
any additional protective effect. 
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Combining submersion with perfusion marginally increases the protective 
effect of ethylene glycol in the subcortical and medullar tissue
In previous reports, we have shown that a combination of submerging in, 
and perfusion with, a solution containing 10% DMSO, extended the protec-
tive effect to the deeper tissue layers of an intact bovine ovary, although in 
these deeper layers complete protection was not achieved. In the next set 
of experiments, we therefore analyzed the protective effect of combining 
submersion in, and perfusion with, DMSO as well as ethyleneglycol (À gure 
2). DMSO treatment resulted in a familiar pattern. Submersion only for 15 
minutes (condition 3) fully protects the cortical ovarian layer while not pro-
tecting the deeper tissues, and combining submersion and perfusion for 30 
minutes (condition 4), on the other hand, still resulted in 100% protection of 
the cortex, while only partially (50-60%) protecting the subcortex and me-
dulla. Combining submersion and perfusion with ethyleneglycol (condition 5) 
increased the protection of the subcortex and medulla compared with sub-
mersion only, but in all tissue layers the protection levels did not rise beyond 
35-40% of the fresh tissue value.
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Figure 2: In vitro glucose consumption of bovine ovarian tissue fragments 
derived from fresh ovaries (condition 1; positive control o), ovaries cryo-
preserved and thawed without any protection (condition 2; negative control 
Ⱦ) and from ovaries incubated in a solution containing 10% DMSO 15 minutes 
prior to cryopreservation (condition 3 Ȼ), ovaries submerged in, and per-
fused with, 10% DMSO for 30 minutes (condition 4 ¹), or from ovaries sub-
merged in, and perfused with, 10% ethyleneglycol for 30 minutes (condition 
5 ¨). Each symbol represents a single ovary. Tissue fragments were collected 
from the ovarian cortex (left panel, the subcortex (middle panel) and from 
the medulla (right panel). Note complete protection against cryodamage of 
cortical fragments derived from ovaries after submersion in and perfusion 
with DMSO, and partial protection of the subcortex and the medulla. With 
ethyleneglycol only about 50% of the protection level of DMSO was observed. 
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Time between removal of the ovary and start of the heparin perfusion is 
crucial for successful cryopreservation of the entire intact ovary
From the experiments described above, we concluded that DMSO was superior 
to the other tested cryoprotective agents, and therefore the cryoprotectant 
of choice for further optimalization of the cryopreservation process. Even 
with DMSO, however, we did not succeed in increasing protection levels of the 
subcortex and the medulla beyond the 50-65% mark, stimulating us to further 
investigate the possible derogatory effects of other aspects of the procedure. 
We postulated that the relatively long period of time at the abattoir (30-40 
minutes) passes between the death of the animal, and the moment when 
we could obtain its ovaries for processing, was a possible Á aw in our bovine 
model system. Obviously, the duration of this time period is dependent on the 
workÁ ow in the abattoir. We were able to adapt this workÁ ow in a way which 
enabled us to obtain the ovaries as early as 10-15 minutes after death of the 
animal. With these ovaries, we repeated a number of experiments with DMSO 
as a cryoprotectant. Results are shown in À gure 3.
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Figure 3. In vitro glucose consumption of bovine ovarian tissue fragments 
derived from ovaries derived from cows that were processed (perfused 
with heparin) 30-50 minutes after their death (light gray bars; “late ova-
ries”) vs 15-20 min after their death (dark grey bars; “early” ovaries). Shown 
is the mean +/- SD; number above bars represents the number of tested 
ovaries per condition. Note increased metabolism of fresh ovarian tissue that 
was obtained as soon as possible after death of the cow. Also the DMSO-me-
diated protection levels against cryodamage are higher (>95% protection) in 
the tissues processed 15-20 minutes after death of the cow, compared with 
tissues processed cows 40-50 minutes after death (50-70% protection).
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The À rst thing we noticed was that the metabolic activity of fresh “early” 
ovaries (i.e. obtained 10-15 minutes after death of the cow; condition 1) 
was signiÀ cantly (P0.0001) higher than the metabolic activity of fresh “late” 
ovaries (i.e. obtained 30-40 minutes after death; condition 10). This was ob-
served in all three tissue layers. After submerging and perfusion the “late” 
ovaries for 30 or 120 minutes with 10% DMSO (conditions 4 and 6 respectively), 
we observed the familiar pattern of completely protected cortex and partially 
protected subcortex and medulla. Although prolonging the incubation from 
30 to 120 minutes led to a slight increase of the protection level (from 60 
to about 75%), complete protection was not achieved. After repeating this 
experiment with “early” instead of “late” ovaries we observed a partial pro-
tection after submerging and perfusion with DMSO after 30 minutes (condition 
7), but a protection of over 90% after a 120 minute incubation time (condition 
8). As our aim was, considering the possible toxic side effects of DMSO, to 
keep the incubation time with DMSO as short as possible, we then tested the 
protective effect of combining submersion and perfusion for an intermediate 
period of 60 minutes. As shown in À gure 3 condition 9, the protection levels 
obtained with this procedure are comparable to a 120 minutes incubation and 
statistically not different (P> 0.05) from the levels of fresh tissue in all three 
layers. 
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DMSO submerging and perfusion protocol also fully protects human ovaries 
against cryodamage
Figure 4: In vitro glucose uptake by fresh and cryopreserved human ovar-
ian tissue fragments. Ovaries derived from three different BRCA-1/2 pa-
tients that had both of their ovaries prophylactically removed. One ovary 
from each patient was used to prepare fresh tissue fragments (positive con-
trol) , and glucose uptake of these fresh fragments was set at 100%. The 
contra lateral ovary of each patient was submerged in en perfused with a 10% 
DMSO solution prior to cryopreservation. After thawing tissue fragments (of 
cortex, subcortex and medulla) were prepared and cultured. Glucose uptake 
is expressed as percentage of the uptake by fresh tissue. Note complete pro-
tection against cryodamage in patients 2 and 3 at all tissue levels, whereas 
the subcortical and medullar tissue from patient 1 has sustained cryodamage.
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After establishing the optimal procedure to protect intact bovine ovaries 
against cryodamage during cryopreservation, we cryopreserved intact ovaries 
from three women, using the optimal protocol. From each patient, one ovary 
was used to prepare tissue fragments that were cultured fresh, whereas the 
contra lateral ovary was perfused with heparin, and cryopreserved using a 
combination of 10% DMSO for submersion and perfusion for 1 hour. Considering 
the importance of starting the perfusion with heparin as soon as possible after 
obtaining the ovary, this perfusion was performed in the operation theatre, 
only minutes after the surgical removal of the ovaries. As judged by the blue 
coloration of the ovary during the perfusion with heparin/methylene blue, 
the second ovary (used for cryopreservation) of patient 1 was not completely 
successful, as only part of the ovary turned blue. Both ovaries from patients 
2 and 3, on the other hand, turned completely blue shortly after start of the 
perfusion. In Figure 4 the glucose consumption of the fresh tissues is put at 
100% to facilitate inter-patient comparisons. In patient 1, the cortical layer of 
the ovary was fully protected against cryodamage, whereas in the subcortex 
and the medulla protection levels of only 30-40% were achieved. In patients 
2 and 3, on the other hand, all three ovarian tissue layers were protected for 
over 90% by applying our optimized cryopreservation protocol. 
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The cryopreservation procedure causes no visible damage to either folli-
cles or the vascular endothelium in the human ovarian tissue
One of the effects of a prolonged incubation time with DMSO, as is required 
in our optimized cryopreservation protocol, is damage to the vascular com-
ponent of the ovary. To assess damage to the endothelium, we performed 
immunohistochemical staining with anti-factor VIII antibody in fresh as well 
as cryopreserved and thawed human ovarian tissue. As shown in À gure 5, no 
apparent damage to the endothelial cells was visible.
 
Figure 5: Fresh and cryopreserved human ovarian tissue stained immu-
nohistochemically with anti-Factor VIII antibody to highlight endothelial 
cells. No apparent damage to the vascular endothelial cell layer is visible 
in the cryopreserved ovaries. Note presence of erythrocytes in the vessels 
of the fresh tissue, which are lacking in the perfused cryopreserved ovarian 
tissue.
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In addition, follicles in fresh and in cryopreserved human ovarian tissue ap-
peared morphologically identical on a light microscopy level (À gure 6). 
Figure 6: Primordial and primary follicles from fresh (panel A and C) and 
cryopreserved/thawed (panel B and D) human ovaries stained with hae-
motoxylin-eosin
Cryopreservation of intact bovine 
and human ovaries without apparent cryodamage
139
Discussion
In this paper we present a procedure to cryopreserve and thaw an intact ovary 
without apparent cryodamage. Perfusion with 10% DMSO for 60 minutes was 
required for complete protection on all tissue levels. A comparable perfusion 
time (40 minutes) required for optimal cryopreservation of bovine ovaries 
with DMSO was reported by Zhang (Zhang et al., 2011). Whilst the majority 
of our data were obtained using bovine ovaries as a model system, our À nal 
experiments with human ovaries show that our bovine data can actually be 
extrapolated to the human situation. 
We have shown that whereas two of our human ovaries were coloured blue 
in their entirety by the methylene blue/heparine perfusion Á uid, one ovary 
was only partly coloured. This observation was reÁ ected in the less successful 
cryopreservation (based on its glucose metabolism) of the latter ovary. Clot 
formation has most likely occurred in this ovary thereby not only preventing 
the heparin/methylene blue solution to completely perfuse the ovary, but 
also hindering the subsequent perfusion with the cryoprotectant solution. A 
complete perfusion of the ovary is evidently a prerequisite for successful 
cryopreservation.
Another factor in our model system which proved to be crucial for successful 
cryopreservation, was the time that elapsed between death of the cow, the 
start of the perfusion with heparin, and cooling of the tissue. By reducing 
this period of time, the condition of the fresh tissue increased considera-
bly, and, in addition, our perfusion with DMSO resulted in a 100% protection 
of the glucose metabolism of the tissue after cryopreservation and thawing. 
When surgically removing a human ovary for cryopreservation, there should 
be theoretically no time lapse between removal of the ovary and start of the 
perfusion, provided that the person performing the perfusion is sufÀ ciently 
experienced in canulating the ovarian blood vessels. However, if other surgery 
has to be performed as well, some surgeons may leave the detached ovary 
in the abdominal cavity during the additional surgery. As our experience with 
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bovine ovaries has shown the ischemia that occurs during this time may lead 
to severe tissue damage, this situation should obviously be prevented.
As far as the choice of the cryoprotectant is concerned, our results indicate 
that on account of this, butanediol and propanediol should not be considered. 
While we saw some cryoprotective effect of ethyleneglycol, in our study DMSO 
proved to be clearly superior. In two European centers for cryopreservation 
of human ovarian cortex strips, both these cryoprotectants are used. Where-
as the University Hospital in Bonn (Germany) uses DMSO, ethyleneglycol is 
the cryoprotectant of choice for the Danish central facility for ovarian tissue 
cryopreservation, the University Hospital of Copenhagen, (Denmark). Both 
centres have reported pregnancies after autotransplantation of ovarian tissue 
fragments (Isachenko et al., 2012; Ernst et al., 2010; Andersen et al., 2012), 
indicating that they are both successful in cryopreserving and autotransplant-
ing of human ovarian tissue. The relative lack of protection against cryodam-
age, which we observed with ethyleneglycol, may be explained by the fact 
that we cryopreserved intact bovine ovaries rather than human ovarian cortex 
strips. In this context, however, it is slightly worrying that in ovaries that were 
cryopreserved using ethyleneglycol, glucose metabolism of the subcortex and 
the medulla was even lower than in ovaries cryopreserved without any form 
of cryoprotection, possibly indicative of a toxic side effect of ethyleneglycol.
Our À ndings are predominantly based on our glucose-lactate metabolism as-
say as a read-out system for cryodamage. As stromal cells comprise more 
than 90% of the ovarian volume, it is safe to say that this assay predominantly 
provides information on the viability of the stromal cell compartment. Assays 
that combine the assessment of metabolic activity with histology, such as the 
methylthiazolyl blue tetrazolium (MTT) assay described by Torre et al. (Torre 
et al., 2012; Torre et al., 2013), may provide valuable additional information 
on the condition and viability of the ovarian stromal tissue on different tissue 
levels. 
Obviously, the condition of the follicles, the internal ovarian vasculature, 
and the vascular pedicle will also have to be assessed before we can safely 
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attempt to cryopreserve and consecutively autotransplant an intact human 
ovary. Although immunohistochemical evaluation of the integrity of the vas-
cular endothelial lining of both large en small bloodvessels did not show any 
gross irregularities in human cryopreserved ovaries, morphological assess-
ment alone is most probably not sufÀ cient. Onions at al. (Onions et al., 2008; 
Onions et al., 2013) used a number of techniques to demonstrate that not 
only the cryopreservation process itself, but also the perfusion technique that 
is used to saturate the ovine ovaries with cryoprotectant, inÁ icted damage on 
several levels. In cryopreserved ovaries, follicle densities were signiÀ cantly 
reduced, and cell proliferation as well as apoptosis were increased. As vascu-
lar endothelial cells are in close contact with the DMSO containing perfusion 
Á uid during the full incubation period, they may be the most vulnerable to 
any possible toxic side effect of DMSO. Damage to the endothelial lining of 
the blood vessels may result in exposure of the underlying basal membrane, 
inducing intravascular clotting after the cryopreserved ovary is retransplant-
ed in the recipient. Evidence of vascular damage in cryopreserved ovine ova-
ries was demonstrated by Onions by the extravasation of Á uorescent micro-
spheres, and the presence of clots in cryopreserved ovaries. On RNA level 
the authors showed a complex pattern of up, as well as, down-regulation of 
several endothelial cell markers including eNOS, endothelin-1 and -2 and en-
dothelin-receptor A, in both cryopreserved and perfusion-only ovaries. It will 
be very interesting to evaluate the effects of the recently described potent 
cryodamage protector sphingosine-1-phosphate (Onions et al., 2008) in this 
model system.
Whether the same cryopreservation-related effects on the vascular endothe-
lium occur in our model system and in human ovaries as well, remains to 
be investigated. An initial proof of concept of our procedure would be the 
successful retransplantation of a cryopreserved bovine ovary into a cow. As 
cows, however, are most probably not sufÀ ciently inbred, rejection of the 
ovarian graft by the recipient is to be expected. We are currently assessing 
other appropriate animal models to perform these experiments, that may 
provide amongst other things, information on the likelihood of post-surgery 
intravascular clot formation.
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The ultimate goal of our studies is of course to transfer them to the human 
situation. In this case, two major obstacles should be considered. Firstly that 
tumour cells, possibly leading to reintroduction of the malignancy after auto-
transplantation, are present in an intact ovary, which poses a much higher risk 
in this situation compared to ovarian cortical strips. Intact ovarian autotrans-
plantation should therefore, only be offered to cancer patients when ovarian 
involvement can be virtually excluded. We have recently performed a sys-
tematic review on the chance of different tumour types metastasizing in the 
ovary (Bastings et al., 2013). Our results show that information relating to the 
likelihood of this occurring is incomplete or lacking completely. We therefore 
recommend, that until more knowledge on this subject has been obtained, 
intact ovary autotransplantation can only be carried out on benign indication. 
Secondly, the inherent risk with cryopreserving and auto transplanting an in-
tact ovary, is that any calamity that may occur sometime during the entire 
process, results in the loss of all the oocytes that are present in the ova-
ry. Clot formation during the autotransplantation is in this respect the most 
prominent risk. In clinical practice, therefore, we suggest that for the time 
being, intact ovary autotransplantation should be offered only to patients 
with a very high (>50%) chance of becoming sterile due to their treatment, 
sanctioning the removal of both of their ovaries. One ovary may be cryopre-
served intact, whereas the second ovary can be used to prepare and cryo-
preserve ovarian cortex strips. These cortex strips may be used as a backup 
strategy, should the autotransplantation of the intact ovary fail.
In conclusion, intact ovarian autotransplantation in humans still has a number 
of obstacles to overcome. However, our optimalized cryopreservation proce-
dure represents an important step in ultimately achieving this goal. 
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General Discussion
As discussed in the introductory chapters of this thesis, several options for 
fertility preservation, including transposition of the ovaries, cryopreserva-
tion of (either mature or immature) oocytes or embryos, or cryopreservation 
of ovarian tissue are now available for girls and young women who have to 
undergo gonadotoxic (mostly anti-cancer) treatment. All these options have 
their speciÀ c advantages and disadvantages. The optimal treatment will have 
to be speciÀ cally chosen for each individual patient depending on the type 
and severity of the disease, the length of time the treatment can be post-
poned and her age, marital status and patient preferences (Diedrich et al., 
2011; Donnez, 2009; Sonmezer and Oktay, 2004;Wallace and Anderson, 2006).
The cryopreservation and subsequent autotransplantation of ovarian cortical 
tissue strips has now led to the birth of at least 23 children worldwide, in-
dicating that this treatment option has now progressed from the laboratory 
stage to an experimental clinical application (Donnez et al., 2011b; Donnez et 
al., 2011a; Donnez et al., 2012). Whereas this procedure offers the possibility 
of fertility preservation to women for whom the other available options are 
not suitable, it is not without its disadvantages. First of all, the ischemic pe-
riod between grafting the tissue and its revascularization results in a substan-
tial loss of precious follicles. Subsequently, the life span of cortical grafts is 
limited, ranging from several months up to seven years (Donnez et al., 2008; 
Donnez and Dolmans, 2009; Oktay and Karlikaya, 2000; Oktay et al., 2001; Tao 
and Del, 2008; Andersen et al., 2012). Secondly, the cortical graft may con-
tain metastasized tumor cells, leading to a reintroduction of the tumor after 
autotransplantation (Rosendahl et al., 2010; Shaw et al., 1996). 
The À rst major drawback (damage due to an ischemic period after graft-
ing) could potentially be overcome by cryopreserving and autotransplanting 
an intact ovary (including its vascular pedicle) rather than cortical strips. A 
successful re-anastomosis will provide immediate reperfusion, thereby limit-
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ing or even preventing ischemic damage. Theoretically, therefore, the ovary 
should retain its endocrine and reproductive functions for many years (Arav 
et al., 2010; Baird et al., 1999; Bedaiwy et al., 2003; Chen et al., 2006; Gra-
zul-Bilska et al., 2008; Imhof et al., 2006; Jeremias et al., 2002; Onions et 
al., 2009; Revel et al., 2004; Wang et al., 2002). Obviously, the cryopreser-
vation and subsequent thawing and transplantation of an intact organ comes 
with its own set of challenges.
Firstly, a cryopreservation and thawing protocol that minimizes cryodamage 
not only to the follicles/oocytes, but also to the stromal cell compartment, 
the ovarian vasculature and the vascular pedicle, should be developed and 
tested. Secondly a surgical procedure has to be developed, that ensures a 
rapid attachment of the ovarian vascular pedicle to the existing circulation, 
without allowing the introduction of vascular thrombosis. Finally, the danger 
of reintroducing the malignancy via metastasized tumour cells that may be 
present in the ovary, has to be addressed. Theoretically, there is an even 
greater risk with an intact ovary than with cortical strips. No autotransplan-
tation of in intact ovary should be performed without À rst having a solution 
for this problem.
Design of a cryopreservation/thawing protocol for an
intact ovary
For obvious ethical and practical reasons, human ovaries are not suitable for 
the elaborate testing of a large number of different cryopreservation proce-
dures, indicating the need for an appropriate animal model. Next, as stated 
above, the optimal cryopreservation procedure should protect all components 
of the ovary. The applied cryoprotective agent should therefore not only be 
delivered to the ovarian cortex, but also to the subcortex and the medulla. 
Finally, a proper monitoring system that is able to quantify the degree of 
(protection against) cryodamage of the tissue should be available. With these 
components in place, an optimal cryopreservation procedure can then be de-
veloped, and subsequently translated to a human setting.
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This thesis has dealt with the following issues. Firstly we selected bovine ova-
ries as our model system, as these are (in contrast to the ovine ovaries that 
are commonly used in other studies (Courbiere et al., 2005; Courbiere et al., 
2006; Arav et al., 2010; Baird et al., 1999; Bedaiwy et al., 2003; Grazul-Bilska 
et al., 2008; Imhof et al., 2006; Jeremias et al., 2002; Onions et al., 2009; 
Revel et al., 2004) very similar to human ovaries with respect to size, cycle 
duration, and number of follicles that mature each cycle. Via perfusion ex-
periments with Indian ink as a marker, we have shown that the cryoprotective 
agent can be delivered to all compartments of the ovary. We have shown that 
perfusing the organ with a heparin solution as soon as possible after its remov-
al from the body is pivotal preventing intravascular thrombosis. Experiments 
with ovaries in which this initial heparin perfusion did not function proper-
ly, clearly showed a compromised subsequent outcome of the cryoprotective 
measures. In our animal model we were not able to control the time that 
elapsed between the death of the cow, and the removal of the ovaries (and 
start of the heparin perfusion) as this was carried out by the workers in the 
abattoir. In the human setting this factor will obviously be more manageable. 
Next, we have developed a cryodamage assay, as in our opinion the existing 
assays (viability assays, electron microscopy, apoptosis assays etc (Arav and 
Natan, 2009; Baird et al., 1999; Bedaiwy et al., 2006; Martinez-Madrid et al., 
2004; Martinez-Madrid et al., 2007; Onions et al., 2009; Wang et al., 2002) 
are, for several reasons, not suitable for our purposes. The in vitro secretion 
of 17beta-oestradiol by follicles that are present in cryopreserved and subse-
quently cultured ovarian tissue fragments has proven not suitable due to the 
very high variability of this assay. General markers for in vitro cell metabolism 
(glucose uptake and lactate production), on the other hand, have proven to 
be a robust and reproducible way to quantify the effects of different cryo-
preservation protocols on the degree of cryodamage in cultured ovarian tissue 
fragments. Using this assay, we determined that a combined method of sub-
merging the ovary in a 10% DMSO solution, while at the same time perfusing it 
with 10% DMSO for 60 minutes results in the most complete protection against 
cryodamage of not only the superÀ cial (cortical) part of the ovary, but also 
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of its medulla. Immunohistochemistry showed no apparent damage to the en-
dothelial cell lining of the ovarian vasculature and the vascular pedicle when 
using this treatment. A limited set of experiments with human ovaries has 
shown that this protocol also protects human ovaries against cryodamage. In 
short, the hurdle of cryopreserving an intact ovary without causing excessive 
amounts of cryodamage appears to have been taken.
The surgical re-anastomosis procedure
A major problem associated with maintaining the viability of an intact ovary 
is to re-establish an adequate vascular Á ow immediately after performing the 
autotransplantation. This procedure requires a difÀ cult microsurgical tech-
nique to perform a vascular anastomosis. In the cow, the arteria ovarica as 
well as the vena ovarica are extremely tortuous, showing many branching 
smaller vessels (displaying a large intra-animal variation), which only have a 
small diameter (1-1.25mm (Lamond and Drost, 1974)). As preliminary attempts 
to xenotransplant a bovine ovary into a rat have shown, to prevent leakage, 
the branching vessels all have to be occluded before a re-anastomosis can be 
attempted. In humans the afferent and efferent ovarian vessels are somewhat 
less convoluted, but also show a considerable amount of branching, and have 
an even smaller diameter (Bedaiwy et al., 2006; Martinez-Madrid et al., 2004; 
Ploteau et al., 2011; Silber, 2012). The surgical procedure will therefore be a 
complicated one. In the few reported intact fresh (non-cryopreserved) intact 
human ovary transplantations, the vascular pedicle was functional for more 
than a year after transplantation (Silber et al., 2008; Hildersi et al., 2004; 
Leporrier et al., 1987). 
Micro surgical vascular re-anastomosis of frozen-thawed ovaries has often 
been associated with thrombosis (Baird et al., 1999; Courbiere et al., 2009; 
Grazul-Bilska et al., 2008; Onions et al., 2009) and a poor functional outcome 
(Chen et al., 2006; Jeremias et al., 2002). If the anastomosis fails, then the 
survival of the intact ovary is irreversibly compromised, and the ovary is lost. 
Jadoul et al suggest that, to overcome this problem, whenever an intact ovary 
General Discussion
153
cryopreservation is attempted, cryopreservation of the cortical strips from 
the contra- lateral ovary should also be carried out which could then be used 
as a back up in the event of re-transplantation failure (Jadoul et al., 2007; 
Jadoul et al., 2010). Yin et al, on the other hand, suggest that one of the two 
ovaries should be left in situ so that an intact pedicle is available for exchang-
ing the sterilized ovary with the frozen and thawed one, once the patient is 
ready for autotransplantation (Yin et al., 2003). This takes into account the 
possibility that the remaining ovary may not have been completely destroyed 
by the chemotherapy.
The safety of the procedure with regard to reintroduction 
of the tumour
A very important issue is the possibility that the tumour is reintroduced to the 
cured patient via metastasized tumour cells that are present in the autotrans-
planted ovarian tissue. This is a distinct possibility especially for patients with 
leukaemia, (Greve et al., 2012; Hou et al., 2007; Kim et al., 2012). Whereas 
this is already a concern for cortical ovarian tissue fragments, this danger is 
theoretically even more daunting when an intact organ is re-transplanted. 
Thus far there are no reports relating to recurrence of malignant disease 
involving transplanted ovarian tissue (Kim et al., 2012). It should be noted, 
however, that the number of transplants is relatively small (although the ex-
act number of transplants, due to the lack of a database is unknown), and the 
duration of follow up is short. 
Evidently, patients need to be extensively counselled with regard to these 
dangers (Anderson et al., 2008). Unfortunately this is hampered by our in-
complete knowledge of the incidence of ovarian metastases in the majority 
of tumour types. Ideally, the presence of tumour cells in the ovarian tissue 
to be transplanted should be assessed for each individual patient c.q. graft, 
for instance by histology (Azem et al., 2010; Rosendahl et al., 2011; Donnez 
et al., 2011b) or PCR techniques (Rosendahl et al., 2010) and xenotransplan-
tation of human ovarian tissue fragments to immune deÀ cient mice (Dolmans 
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et al., 2010). Unfortunately, for most tumour types, tests that are sufÀ ciently 
sensitive and speciÀ c are lacking. In addition, the tissue that is used for the 
analysis is per deÀ nition not the tissue that will be transplanted, thereby 
limiting the value of these diagnostic tests. In the future should a malignant 
contamination of the tissue that is to be transplanted be conÀ rmed, (imma-
ture) oocytes may be harvested, matured in vitro, and subsequently used for 
in vitro fertilization in order to circumvent the risk of tumour reintroduction.
Introduction into the clinic
To avoid unwanted side effects, the application of the technique of freezing 
and transplantation of an intact ovary will have to be performed via a step by 
step protocol. The initial patient group that would be suitable to receive this 
type of treatment, would have to meet the following criteria:
a. Malignant disease: gonadotoxic treatment with high chance (>50%) of 
actually causing infertility. 
b. Non-malignant disease (e.g. SLE, sickle cell disease, glomerulonephri-
tis) because prevention of reintroduction of the tumor is not an issue 
(Gidoni et al., 2008). 
For these patients it may be advisable to cryopreserve one ovary intact, and 
prepare cortical strips from the contralateral ovary that remains in situ. 
Should the re-transplantation of the intact ovary fail, then the patient has an 
additional option for restoration of her fertility.
Next to these clinical contemplations, a number of practical and logistic pa-
rameters will have to be taken into consideration. To date, the cryopreserva-
tion of ovarian tissue or intact ovary with the aim to preserve fertility is not 
covered by health insurance in The Netherlands. Therefore, at this moment, 
the costs of the procedure are paid for by the hospital in which the procedure 
is performed. Considering the complex nature of the procedure (including 
counseling, surgery, laboratory procedures and long storage of the tissue or 
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an intact ovary), and consequently, its high costs, this is not a situation that 
can be maintained indeÀ nitely. The cost of the procedure could be reduced 
by concentrating this type of fertility preservation to a limited number of 
hospitals, thereby centralizing and minimizing the necessary equipment and 
expertise. In surrounding countries this choice has already been made. The 
ovaries are removed in the local hospital that is already treating the patient, 
and is then transported to one (Denmark), or a limited number (Germany) of 
central facilities, that subsequently prepare the cortical strips, cryopreserve 
and store them. Finally, an international database that registers the number 
of ovarian tissue transplants, their clinical outcome and follow up, should 
be established. The ESHRE Task Force on Fertility Preservation and the In-
ternational Society for Fertility Preservation (ISFP) should play an important 
initializing and coordinating role in this matter (Kim et al., 2012).
Concluding remarks 
In conclusion, the cryopreservation and subsequent autotransplantation of 
an intact ovary may, in the future, be an alternative option for a particular 
group of patients that seek fertility preservation. It is also clear, however, 
that a great deal of additional research will have to be carried out before any 
clinical tests can be performed. The glucose/lactate assay, developed by us, 
may be a valuable tool in delineating and À ne-tuning the deÀ nitive protocol, 
which may be a combination, and perhaps even a compromise,separated from 
all the other protocols. Obviously, the vitality of the cell types, especially the 
follicles, in cryopreserved ovarian cortical strips will have to be assessed in 
parallel.
In addition, the risk of ovarian metastases should be investigated and evalu-
ated for (at least) the most prominent tumour types, and strategies should be 
developed to minimize or even eliminate the risk of tumour reintroduction. 
Finally, autotransplantation of cryopreserved intact ovary in humans still has 
a number of hurdles to take. While no human studies of intact ovary trans-
plant after cryopreservation have been performed, studies in large animals 
(e.g. Baboons and Primates) have been encouraging. 
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Summary
Ovarian tissue cryopreservation and transplantation is an option for fertility 
preservation in women at risk of losing their ovarian function due to can-
cer therapy. Cryopreservation and transplantation of cortical strips has been 
carried out extensively, with success, resulting in the birth of several babies 
worldwide. Despite these encouraging results, some signiÀ cant concerns still 
overshadow this procedure and its achievements. An important factor is the 
ischemic damage which occurs during the time needed for revascularization 
of the transplanted tissue. A better alternative is possibly intact ovary cryo-
preservation and transplantation with vascular anastomosis. The purpose of 
this thesis is to design an optimal cryopreservation protocol for an intact ova-
ry. Although several studies have been published on this topic these generally 
use animal model systems with smaller and much more easier to preserve 
ovaries. Furthermore, the extent of cryodamage to these cryopreserved in-
tact ovaries remains rather unclear. This thesis aims to highlight the different 
aspects of cryopreservation on an intact ovary.
In chapter 1 a general introduction is represented in which the aims of this 
thesis are formulated. The aim of the study is to establish the optimal pro-
cedure for cryopreservation of a intact ovary. We develop an assay based 
on 17ş-oestradiol production in vitro as a marker for (pre-antral) follicular 
survival as well as an assay based on the glucose/lactate metabolism as a 
quantitive parameter of cryodamage on ovarian tissue. After optimization of 
the technique a few human ovaries will be cryopreserved and tested.
In chapter 2 a review on ‘’ Fertility preservation for pre-pubertal girls and 
young female cancer patients ‘’ is given. Basic oocyte biology and effects 
of radio- and chemotherapy on female fertility are presented. Current and 
future options for fertility preservation are described in detail, focusing on 
cryopreservation of ovarian tissue. 
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In chapter 3 we demonstrate the suitability of bovine ovaries as a substitute 
for human ovaries to explore the perfusion procedure that is required for cry-
opreservation of intact ovaries. The ovarian artery is cannuled, and ovaries 
are Á ushed with Indian ink for 5 min. Successful perfusion of blood vessels is 
immediately visible macroscopically by a grey to black discoloration of the 
ovary. This is conÀ rmed microscopically, by the examination of tissue sec-
tions. The percentage of perfused vessels increases with an increase in vessel 
size. In a limited set of preliminary experiments with human ovaries, compa-
rable results are obtained. Our results show that bovine ovaries are a suitable 
and adequate model system for optimizing the cryopreservation in human 
ovaries. Considering that bovine ovaries are of a comparable size, anatomy 
and function to human ovaries, we expect our results to be transferable to 
the human situation.
To date it is unknown which procedure can best be used in the successful 
cryopreservation of the human ovary, without inÁ icting a devastating level of 
cryodamage on the ovary itself.
In chapter 4 we describe an assay based on 17ß-oestradiol production, to 
monitor the functional damage sustained by the ovarian tissue during the 
freezing/thawing procedure. Fresh bovine ovarian cortical biopsies are cul-
tured in vitro for 7 days. As a control, the oestradiol levels released by bi-
opsies that had sustained maximal cryodamage are analyzed. In addition the 
oestradiol released by cortical biopsies from two dimethylsulphoxide (DMSO) 
perfused and cryopreserved intact ovaries is also analysed. Oestradiol produc-
tion could be measured in culture supernatants, while oestradiol released by 
maximal cryodamaged biopsies is found to be virtually absent. Unfortunately, 
the high degree of variation in levels of E2 production renders this assay un-
suitable to test a large number of alternative cryopreservation protocols in an 
efÀ cient and reliable fashion.
As an alternative assay to examine cryodamage to cryopreserved intact ova-
ries, in chapter 5 the development of an assay based on measuring glucose 
and lactate metabolism of ovarian tissue fragments in vitro is presented. 
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We show that the uptake of glucose and the production of lactate are repro-
ducible markers for the amount of cryodamage sustained by cryopreserved 
ovaries.
Using this assay we have tested the cryoprotective effect of two different 
administration routes of the cryoprotectant DMSO. The cryoprotective effect 
is assessed in different tissue layers of the ovary, namely the cortex, the sub-
cortex and the medulla. Whereas submersion of intact ovaries in DMSO prior 
to freezing–thawing resulted in a complete protection of the cortex, perfusion 
with DMSO is required for a partial protection of the inner ovarian mass. A 
combination of submersion and perfusion demonstrated the highest level of 
protection for all three ovarian tissue layers. 
In chapter 6 we elaborate on the experiments described in chapter 5, to 
optimize the protection of the inner ovarian mass. We have analyzed several 
other variables that might contribute to a more efÀ cient protection of the 
sub cortical and medullar layers. To this end the cryoprotective effects of 
several other cryoprotectants (propanediol, ethyleneglycol, butanediol) are 
analyzed. In addition we have varied the time of the perfusion procedure. 
From these experiments it has become clear that DMSO is by far the best 
cryoprotectant and that a perfusion period of 1 hour is required for a 90-100% 
level of protection of the inner ovarian mass. Immunohistochemistry with 
anti-endothelial cell markers shows that this prolonged perfusion procedure 
appears to be well tolerated by the vasculature. Finally we have shown that 
start of perfusion of the ovary with a heparin solution within 10 minutes of the 
death of the animal (cow) is a prerequisite for a successful subsequent per-
fusion with cryoprotectant. A longer period of time between death and start 
with the heparin perfusion results in intravascular blood clot formation and 
hence a suboptimal perfusion with cryoprotectant. We also have applied our 
optimised cryopreservation protocol to a limited number of human ovaries 
and have shown that our results with bovine ovaries can actually be extrapo-
lated to human material with comparable results.
 
Chapter 8
166
In chapter 7 the results of this thesis are discussed and perspectives for fu-
ture studies are presented. Techinical challenges have to be overcome for 
the freezing/thawing of intact ovaries with animal experiments À rst and then 
with human ovaries. The glucose/lactate assay, developed by us, is a valuable 
tool in delineating and À ne-tuning the deÀ nitive protocol.
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Samenvatting
Cryopreservatie van ovarieel weefsel, gevolgd door transplantatie, is een 
manier om bij vrouwen die het risico lopen de functie van hun ovaria te ver-
liezen door de behandeling van kanker, de kans op vruchtbaarheid te behoud-
en. Cryopreservatie en transplantatie van ovariële corticale strips is al uitvo-
erig bestudeerd en uitgevoerd, resulterend in de geboorten van een aantal 
baby’s wereldwijd. Ondanks deze bemoedigende resultaten, kleven er toch 
nog grote problemen aan deze behandeling. Een belangrijk probleem is de 
ischemische schade die kan ontstaan gedurende de tijd die nodig is voor de 
revascularisatie van het getransplanteerde weefsel. Het cryopreserveren van 
een intact ovarium en transplantatie met vaatanastomoses zou een beter al-
ternatief kunnen vormen. Het doel van dit proefschrift is een optimaal proto-
col te ontwerpen voor het cryopreserveren van een intact ovarium. Hoewel er 
reeds een aantal studies over dit onderwerp gepubliceerd zijn, werden hierbij 
in het algemeen diermodellen met kleinere dan humane, hierdoor makkelijk-
er te cryopreserveren, ovaria gebruikt. Bovendien blijft, in de literatuur, de 
uitgebreidheid van de opgetreden vriesschade van het gecryopreserveerde in-
tacte ovarium tamelijk onbekend. Dit proefschrift heeft als doel de verschil-
lende aspecten van de cryopreservatie van een intact ovarium te belichten.
In hoofdstuk 1 wordt een algemene inleiding gegeven en de doelstelling van 
dit proefschrift geformuleerd. Het doel van de studie is een optimale proce-
dure te ontwikkelen om een intact ovarium te cryopreserveren. We ontwik-
kelen een “assay” gebaseerd op een 17ş-oestradiol productie in vitro als een 
marker voor de overleving van (pre-antrale) follikels. Eveneens ontwikkelen 
we een “assay” gebaseerd op het glucose/lactaat metabolisme als een quan-
titatieve parameter van vriesschade aan het ovarieel weefsel. Na de optimal-
isatie van de techniek van de cryopreservatie worden enige humane ovaria 
gecryopreserveerd en getest.
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In hoofdstuk 2 wordt een overzicht ‘’ Behoud van de vruchtbaarheid van 
pre-puberale meisjes en jonge vrouwen met kanker ’’ gegeven. Basale biolo-
gie van de eicel en effecten van bestraling- en chemotherapie op de vrucht-
baarheid van de vrouw worden besproken. Huidige en toekomstige opties voor 
het behoud van de vruchtbaarheid worden in detail beschreven, toegespitst 
op de cryopreservatie van ovarieel weefsel.
In hoofdstuk 3 laten we de bruikbaarheid van koeien ovaria zien als een al-
ternatief voor humane ovaria om de perfusie procedure te onderzoeken die 
essentieel is voor een optimale cryopreservatie van intacte ovaria. De ovaria 
worden, d.m.v. een canule via de arterie van het ovarium, doorspoeld met 
Oost Indische inkt gedurende 5 minuten. Succesvolle perfusie van de bloed-
vaten wordt direct macroscopisch zichtbaar gemaakt door de grijs/zwarte 
verkleuring van het ovarium. Dit kan microscopisch worden bevestigd door 
de beoordeling van weefsel coupes. Het percentage van doorspoelde vaten 
neemt toe met het groter worden van de diameter van de vaten. Bij een bep-
erkt aantal experimenten met humane ovaria worden vergelijkbare resultaten 
verkregen. Onze resultaten laten zien dat koeien ovaria een geschikt en goed 
model systeem zijn voor optimale cryopreservatie van humane ovaria. Ervan 
uitgaande dat koeien ovaria, qua grootte, anatomie en functie vergelijkbaar 
zijn met humane ovaria, verwachten we dat onze resultaten extrapoleerbaar 
zijn naar de humane situatie. 
Tot op heden is het onbekend welke procedure het best gebruikt kan worden 
bij het succesvol cryopreserveren van het humaan ovarium, zonder dat het 
ovarium schade oploopt door de cryopreservatie.
In hoofdstuk 4 hebben we een “assay” ontworpen waarin wij de functionele 
schade meten van ovarieel weefsel na vriezen/ontdooien m.b.v. 17ş-oestra-
diol productie. Verse biopten van de cortex van koeien ovaria zijn in vitro 
gekweekt gedurende 7 dagen. De oestradiol productie blijkt gemeten te kun-
nen worden in het supernatant van de gekweekte biopten. De oestradiol (E2) 
spiegels bepaald in biopten die maximale vriesschade hebben geleden, gelden 
als controle. Hierbij blijken deze E2 spiegels nagenoeg onmeetbaar laag te 
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zijn. Vervolgens werden de E2 spiegels van corticale biopten afkomstig van 
2 met dimethylsulphoxide (DMSO) geperfundeerde en gecryopreserveerde in-
tacte ovaria gemeten. Hierbij bleek dat de E2 spiegels dusdanig variëren dat 
deze test minder geschikt is om een groot aantal variaties in het cryopreser-
vatie protocol op een efÀ ciënte en betrouwbare manier te beoordelen.
Als een alternatieve test om vriesschade bij gecryopreserveerde intacte ovar-
ia te onderzoeken wordt in hoofdstuk 5 een test ontwikkeld gebaseerd op 
de bepaling van glucose en lactaat metabolisme in vitro van ovarieel weef-
sel. We laten zien dat de opname van glucose en de productie van lactaat 
reproduceerbare markers zijn voor de hoeveelheid ontstane vriesschade bij 
gecryopreserveerde ovaria. Gebruikmakend van deze test hebben we het cry-
opreserverend effect onderzocht van twee verschillende toegepaste toedi-
enings wijzen van het cryoprotectant DMSO. Het cryoprotectieve effect is in 
de verschillende weefsellagen van het ovarium vastgesteld, t.w. de cortex, 
de subcortex en de medulla. Terwijl onderdompeling van intacte ovaria in 
DMSO, vooraf gaande aan invriezen/ontdooien resulteert in een complete 
bescherming van de cortex, is perfusie met DMSO vereist om een gedeelteli-
jke bescherming van de inwendige ovariële massa te geven. Een combinatie 
van onderdompeling en perfusie laat het hoogste niveau van bescherming zien 
voor al de drie ovariele weefsellagen. 
In hoofdstuk 6 werken we de experimenten, beschreven in hoofdstuk 5, verd-
er uit ten einde de bescherming van de inwendige ovariële weefsel massa te 
optimaliseren. We hebben diverse verschillende variabelen onderzocht die 
mogelijk bijdragen aan een effectievere bescherming van de subcortex en 
medulla lagen. Met dit doel zijn de cryoprotectieve effecten van verschillen-
de andere cryprotectants (propanediol, ethyleneglycol, butanediol) geanaly-
seerd. Bovendien hebben we de tijd van de perfusie procedure gevarieerd. 
Uit deze experimenten is duidelijk naar voren gekomen dat DMSO bij uitstek 
het beste cryoprotectant is en dat een perfusie tijd van 1 uur vereist is om 
een 90-100% bescherming van de binnenste ovariële massa te bereiken. Im-
munohistochemie met endotheel cel markers laat zien dat deze langdurige 
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perfusie procedure goed verdragen lijkt te worden door de bloedvaten. Ten-
slotte laten we zien dat de start van de perfussie van het ovarium met een 
heparine oplossing, binnen 10 minuten na de dood van het dier, een eerste 
vereiste is voor een succesvol verlopende perfusie met cryoprotectant. Een 
langere tijdsperiode tussen de dood en start met de perfusie van heparine 
oplossing resulteert in intravasculaire bloedstolsel vorming en dientengevolge 
een suboptimale perfusie met cryoprotectant. We hebben ons geoptimali-
seerde cryopreservatie protocol ook toegepast bij een beperkt aantal hu-
mane ovaria. We laten zien dat onze resultaten bij koeien ovaria feitelijk 
geëxtrapoleerd kunnen worden naar het humane materiaal met vergelijkbare 
resultaten.
In hoofdstuk 7 worden de resultaten van dit proefschrift bediscussieerd en 
perspectieven voor toekomstige studies gepresenteerd. Technische proble-
men moeten eerst opgelost worden voor het invriezen/ontdooien van intacte 
dierlijke ovaria, alvorens deze procedure bij humane ovaria is toe te passen. 
De glucose/lactaat assay, door ons ontwikkeld, is een waardevolle aanvulling 
in de ontwikkeling en verÀ jning van een optimaal cryopreservatie protocol. 
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Dankwoord
Tijdens de jaren van inspanning voorafgaande aan het verschijnen van dit 
boekje, heb ik vaak gedacht en gezegd: “dit moet in mijn dankwoord”. 
Daardoor dreigt dit hoofdstuk mogelijk het langste te worden van het 
boekje. 
Eigenlijk is alles in januari 1998 begonnen, tijdens een nachtvlucht Miami 
- Amsterdam. Het toeval wilde, dat ik de gehele vlucht naast Didi Braat 
zat, de latere hoogleraar en mijn promotor. We spraken langdurig over het 
lukken en mislukken van mijn wetenschappelijke carrière. Toch duurde het 
daarna nog ruim 6 jaar voordat we het gesprek voortzetten tijdens een 
lunch in het Streekziekenhuis Koningin Beatrix (SKB) te Winterswijk.
Allereerst dank aan mijn promotor, professor dr. D.D. M. Braat, beste Didi:
Nooit zal ik je opmerking vergeten: “..........niks te oud (we delen het 
geboortejaar)....we slepen je erdoor”. Ik voelde me gelijk 20 jaar jonger. 
Door jouw enthousiasme, positiviteit  en vertrouwen in het onderzoek en 
mijn persoon, heb ik het eindpunt gehaald. Het moment van het opsteken 
van de koeienkaars is aangebroken. En ook als de kaars is opgebrand, zal ik 
nooit de kans die je me gegeven hebt, vergeten.
Mijn co-promotor, dr. C.C.M. Beerendonk, beste Ina:
Naast je betrokkenheid van het eerste uur, wist je ook een potje te vinden 
met een gedeelte van het startkapitaal dat nodig was om het onderzoek een 
aanvang te laten nemen. Je begreep ook heel goed wat korte nachtrust, 
na een drukke dienst betekende, om vervolgens À t in het slachthuis de 
koeienovaria te “bewerken”.  Dank ook voor je  altijd opbouwende kritiek 
en geduld.
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Mijn co-promotor, dr. J.R. Westphal, beste Hans:
Veel dank ben ik jou verschuldigd, voor al het geduld en ook je relativerend 
vermogen en geweldige begeleiding. Het feit dat je in het begin met me 
meeging naar het slachthuis, betekende voor mij niet alleen een praktische 
hulp. Ook al hebben we geen fossielen gevonden in de steengroeve in 
Winterswijk, je bezoeken samen met Ron, zijn voor mij een waardevolle 
herinnering en ten alle tijde voor herhaling vatbaar. Heel veel dank 
en hopelijk ook na de promotie nog een voortzetting van de ontstane 
vriendschap. 
Mijn co-promotor, dr. R. Peek, beste Ron: 
Met je komst in januari 2008 raakte het onderzoek in een stroomversnelling. 
Al heel snel wist je het onderzoek À nancieel veilig te stellen door 
geldelijke ondersteuning aan te vragen en te verkrijgen van Pink Ribbon 
en KIKA.  Heel veel heb ik van je geleerd en misschien ook afgeleerd. 
Het laboratoriumwerk viel niet altijd goed en het nauwgezet pipetteren 
zal nooit een echte hobby van me worden.  We hebben bijna 6 jaar elke 
donderdag samen doorgebracht in het slachthuis en het “vuile lab”. Heel 
wat afgediscussieerd, gelachen en geprepareerd op beide locaties. Met 
humor konden we de teleurstellingen en soms de wat bloederige omgeving 
het hoofd bieden. Sinds die tijd hebben we een andere kijk op de koe 
gekregen. Door jouw inventieve denkwijze heeft wetenschap een hele 
mooie betekenis voor mij gekregen. Overigens hebben jouw bezoeken 
op de operatieafdeling in het SKB ook de nodige positieve indrukken 
achtergelaten. Maar ook buiten die afdeling ben je altijd welkom in 
Winterswijk (fossielen of reptielen zoeken?). 
Verder dank aan: 
De leden van de manuscriptcommissie, prof. Van Krieken, prof. D’Hooghe en 
dr. Vos wil ik natuurlijk hartelijk bedanken voor hun tijd en moeite om het 
manuscript kritisch te lezen.
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De medewerkers van het Fertiliteit Laboratorium van het Radboudumc 
en in het bijzonder José Verbeet, Hannie Robben en Emiel Lindeman voor 
een aantal bezoeken met mij, ter ondersteuning, aan het slachthuis. 
Ook voor de vele malen, op zaterdagochtend, jullie medewerking met de 
overplaatsingen van de ovaria uit Mr. Frosty naar de vloeibare stikstof. En 
Hannie dank voor de mooie weefsel coupes.  Door de inzet van Anneke van 
de Punt- van der Zalm was het mogelijk met steriel instrumentarium aan het 
werk te gaan.
Het personeel van het Slachthuis Nijmegen B.V. en in het bijzonder de heer 
C. van Vught, als toenmalig directeur die toestemming verleende om het 
slachthuis te bezoeken. Walter Thijssen en Pim Reinders, niets was jullie te 
gek of moeite te veel, als we zo onze wensen hadden met betrekking tot het 
aanleveren van de koeienovaria. Zonder jullie hulp had het onderzoek niet 
kunnen slagen.
Het personeel van de operatieafdeling in het SKB en in het bijzonder Joke 
Overkamp voor het bij elkaar zoeken van de juiste naaldjes, kathetertjes en 
pincetjes. Ook werd de operatie microscoop ter beschikking gesteld aan Ron 
Peek, direct naast de OK.  Ronald Nienhuis bedacht het gebruik van de juiste 
naaldjes en leende deze vervolgens van de oogarts. Verder iedereen die 
regelmatig informeerde of ik al opschoot met mijn onderzoek.
De 6 patiënten, die mee wilden werken aan het onderzoek en op deze 
manier voor de toekomst een mogelijke bijdrage aan het levensgeluk van 
anderen kunnen leveren. Lieve patiënten, die na de goede aÁ oop van de 
operatie, direct informeerden of het onderzoek ook goed was verlopen.  
De afdeling Pathologie Laboratorium Enschede, met name drs. R. Vink,
beste Robert:
Dank voor je deskundige beoordeling van het weefsel, aangeboden na 
het doorlopen van het onderzoek. De aanwezige ponsgaten in de ovaria, 
deerden je in het geheel niet.
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Het personeel van Vrouw/Kind in het SKB dat ook altijd zeer geïnteresseerd 
was  in mijn wekelijkse uitstapjes op donderdag, naar Nijmegen. Ook was 
men gewend aan de vraag naar steriele handschoenen en infuussetjes voor 
de koeien. 
De medewerkers van de afdeling Sterilisatie van het SKB die, met veel 
enthousiasme, “afgedankte” operatie instrumenten doneerden voor mijn 
koeienonderzoek. De ex-Oostblok landen hadden in mij een geduchte 
concurrent.   
De ziekenhuisapotheker van het SKB, Henk Hooites Meursing, voor de 
Heparine ampullen. Eveneens werd opeens een forse toename van het 
gebruik van methyleenblauw gezien.
Mijn collegae, Diana van der Borden, Natasja van Loenen en mijn ex-collega 
Hetty de Rooij, wil ik graag bedanken voor het in mij gestelde vertrouwen 
en het, zo nodig, ‘s ochtends om 6.00 uur overnemen van de dienst. Op deze 
manier was ik vrijwel altijd op tijd in Nijmegen. En dank gedurende alle 
jaren voor de interesse in het verloop van het onderzoek. 
Mijn paranimf Jos van Berkel: de basis van onze vriendschap werd 40 jaar 
geleden gelegd bij de introductieweek, in 1973, van de Geneeskunde studie. 
Na lief en leed gedeeld te hebben en een lange “pauze” in onze nimmer 
eindigende vriendschap, ben ik zeer blij dat je aan mijn zijde wilt staan.
Mijn paranimf, Max Colombijn: als collega, kinderarts in Gorinchem, begin  
jaren ‘90 ontstond een vriendschap, die hopelijk nog vele jaren zal duren. 
Ik heb je al heel prematuur (bijna immatuur) gevraagd mijn paranimf te 
worden. Veel dank voor je aanvaarding van deze functie en dat je mij nu 
terzijde staat. 
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Begin 2005 heb ik mijn onderwerp bepaald. Ik wilde ovarieel weefsel 
cryopreserveren.  De interesse in het ovarium ontstond in 1983 na een 
“vurige” voordracht van dr. Theo Kruip, wetenschapper bij Diergeneeskunde 
te Utrecht.  Aangestoken door zijn enthousiasme, hield ik me onder zijn 
begeleiding, enige jaren bezig  met eicel maturatie in vitro bij koeien. 
Een onderzoek dat, naast mijn eerste slachthuis bezoeken, resulteerde 
in een artikel. Een vervolg bleek niet haalbaar, daar ik mijn opleiding tot 
gynaecoloog op dat moment voorrang gaf. De haast om gynaecoloog te 
worden en de drukte die volgde in een perifere praktijk, was de oorzaak dat 
de wetenschappelijke carrière in een slapende fase geraakte. Theo is helaas 
een aantal jaren geleden overleden, maar in gedachte heb ik hem veel 
betrokken bij mijn onderzoek.
Een droom was eigenlijk om de gehele eierstok in te vriezen in plaats van 
een strip. De grote problemen die zich hierbij voordeden, vormden een 
grote uitdaging. Ik realiseerde me ook, gezien de ethiek rondom deze 
materie en de trage voortgang, dat ik pas in 2030 zou gaan promoveren. 
Dit was de reden om weer terug te keren naar het slachthuis om met 
koeieneierstokken te gaan experimenteren.
Omdat ik een fulltime gynaecoloog ben en geen aanspraak kan maken op 
een À nanciële tegemoetkoming uit een studentenpot diende ik de benodigde 
geldstroom zelf  te ontwikkelen. De eerste À nanciële donatie  kwam van de 
Ridderlijke Duitsche Orde - Utrecht.  Deze royale gift is tot stand gekomen 
doordat onze vriendin Conny haar vader, J.D.C. Baron van Heeckeren van 
Kell,van het belang van het onderzoek wist te overtuigen. Conny ging zo 
ver, dat de opbrengst van een collecte tijdens een voor haar persoonlijke 
kerkelijke plechtigheid gedeeltelijk ten bate gesteld werd aan mijn 
onderzoek. Lieve Conny, dit vergeet ik nooit.
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De Firma De Leeuw Huiden uit Winterswijk schonk belangeloos een 
aanzienlijk bedrag! Beste Ria en Menno, de koehandel heeft ons beiden 
zeker geen windeieren gelegd!
Tijdens de bruiloft van mijn neef Jeroen bleken gesprekken over de 
wetenschap tot grote investeringen te kunnen leiden. Beste Anjo Joldersma 
dankzij jouw belangeloze gulle gift heb ik de eerste 2 jaar van de 
onderzoeksperiode kunnen overbruggen.
Mijn zussen Catharina en Gré gaven mij naast mentale, ook À nanciële steun 
om een begin te maken met het onderzoek. Waarvoor mijn dank, die verder 
gaat dan de familieband vereist.    
Jeroen en Nadia Biesbroek wil ik bedanken voor de hulp bij de lay-out van 
het manuscript en de gastvrije toegang tot, en inbreng van Multicycle.
Mijn dochter Ellen dank ik voor de hulp om Reference Manager wat 
inzichtelijker te maken. Zoon Maarten wist na de recente crash van de 
laptop de schade te beperken. De hulp van kinderen is ook meer mogelijk 
(en noodzakelijk ?!) door op latere leeftijd te promoveren.
Tenslotte, zoals de traditie het wil als laatste, mijn allerliefste Janne: je 
hoort op de eerste plaats. Zonder jou was ik niet meer begonnen aan die 
lange wetenschappelijk weg. We hebben het de laatste jaren niet altijd 
even gemakkelijk gehad, maar we krijgen nu de wind in de zeilen. Hopelijk 
kunnen we nog veel tijd samen in ons “atelier” doorbrengen om nog veel 
Janne/RenneG producten te maken. Jij alleen weet wat dit alles voor mij 
betekende en je steun en liefde zal ik nooit vergeten.
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Curriculum vitae
Renne Gerritse werd geboren op 20 augustus 1954 te Rotterdam. In 1973 
behaalde hij het H.B.S.-B diploma aan het Johannes Calvijn Lyceum te 
Rotterdam. In hetzelfde jaar startte hij zijn studie Geneeskunde aan de 
Erasmus Universiteit te Rotterdam. In 1979 behaalde hij zijn artsexamen 
waarna ruim 1 jaar militaire dienstplicht volgde, als arts-assistent op de 
afdeling Plastisch Chirurgie ( hoofd: dr. W. Rijnders), in het Militair Hospitaal 
Dr. A. Mathijsen. Vervolgens verrichtte hij bijna 1 jaar wetenschappelijk 
onderzoek in het Laboratorium voor Experimentele Cardiovasculaire Chirurgie, 
A.Z.U., hoofd: Prof. dr. G. A. Charbon. Van februari 1982 tot en met februari 
1987 werd hij opgeleid tot gynaecoloog in het cluster Utrecht in de volgende 
klinieken: Academisch Ziekenhuis Utrecht te Utrecht (Prof. dr. A.A. Haspels), 
en het voormalig St. Josef Ziekenhuis te Eindhoven (dr. J.H.J.M. Meuwissen).
Van 1 februari 1987 t/m 30 juni 1998 was hij, in de maatschap gynaecologie 
(samen met drs. F. Kragt en drs. W.B.J. Funk), als gynaecoloog werkzaam 
in het Beatrix Ziekenhuis te Gorinchem. Vanaf 1 juli 1998 tot heden is hij 
werkzaam in het Streekziekenhuis Koningin Beatrix te Winterswijk op de 
afdeling Vrouw/Kind. In vakgroepverband al vele jaren collega van Diana van 
der Borden en Natasja van Loenen en sinds kort van Gaby Koch. Parallel aan de 
fulltime baan gynaecoloog startte hij in 2005 het wetenschappelijk onderzoek 
wat uiteindelijk geleid heeft tot dit proefschrift. Als parttime onderzoeker 
was hij werkzaam in het Radboudumc bij de pijler Fertiliteit (promotor 
Prof. dr. D. D. M. Braat en co-promotores dr. C.C.M. Beerendonk, dr. R. Peek 
en dr. J. R. Westphal) en rondde daar zijn promotieonderzoek af.
Hij is getrouwd met Marianne van der Wiel en vader van Frank, Ellen en 
Maarten.
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bij deze plechtigheid.
Receptie ter plaatse
na aﬂ oop van de promotie
Renne Gerritse
Paranimfen
Jos van Berkel
jfjm.vanberkel@vumc.nl
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